Author,Year of publication,Title of paper,Country/Countries,Study Design,Study Period,Setting,Total Sample Size (N),Population Description,Inclusion Criteria,Exclusion Criteria,Age (Mean/Median & SD/IQR),Sex (%Female),Surgical Speciality,Specific Procedures,Intervention Group (N),Intervention Details,Comparator Group (N),Comparator Details,Adherence to Guidelines (%),Total Procedures,Total SSIs,SSI Incidence Rate,Method of SSI Diagnosis,Total SSI Isolates,Pathogen 1 Name (Name of the most common isolated pathogen),Pathogen 1 Resistance (List antibiotic resistance),Pathogen 2 Name (Name of the 2nd most common pathogen),Pathogen 2 Resistance (List antibiotic resistance %),Pathogen 3 Name (Name of the 3rd most common isolated pathogen),Pathogen 3 Resistance (List antibiotic resistance),Resistance to WHO Critical Abx (Any specific data on resistance to WHO critical important antibiotics),Morbidity - Additional Hospital Stay (days),Morbidity - Re-opertation rate (%),Morbidity - Readmission rate (%),Mortality - SSI attributable rate (%),Mortality - 30-day post-op,Mortality - 90-day post-op (%),Hospital burden - Total length of stay (days),Economic - direct costs,Economic - indirect costs,Reported Drivers of AMR,Interventions/Innovations Described,Gaps Identified by Authors,Policy Response/Capacity,Risk of Bias Tool Used,ROB Assessment,Key Author Conclusions,Reviewer Notes
"Akoachere Jane-Francis Tatah Kihla, Palle John Ngunde, Mbianda Soupsop Evelyn, Nkwelang Gerard, Roland Ndip Ndip",2014,"Risk factors for wound infection in health care facilities in Buea, Cameroon: aerobic bacterial pathogens and antibiogram of isolates",Cameroon,Cross-sectional observational study,October 2010 - March 2011,"Mount Mary Health Center (private) and Regional Hospital Annex (public), Buea, Cameroon",212,"Hospitalized patients of all ages with clinically diagnosed infected wounds (including burns, ulcers, open wounds, and post-operative wounds)",Patients hospitalized and clinically diagnosed with wound infection; consent to participate; wounds with purulent discharge or signs of inflammation,Patients without clinical diagnosis of infected wound; patients who did not give consent,Range 7 months to 80 years; Age group breakdowns provided but no mean/median or SD/IQR,42%,"General Surgery (includes post-operative wounds, burns, ulcers, open wounds)","Not specified (includes surgical wounds, burn wound care, ulcer and open wound management)",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,169,79.70%,"Clinical diagnosis based on purulent discharge or signs of inflammation (erythema, pain, tenderness, warmth or induration); aerobic bacterial culture",169,Staphylococcus aureus,"Resistant to oxacillin (100%), chloramphenicol (95.8%), erythromycin (97.9%), co-trimoxazole (100%), doxycycline (79.2%), ampicillin (95.8%), ceftazidime (52.1%). Exhibited multidrug resistance (CAZR SXTR DXTR CR ER AMPR).",Pseudomonas aeruginosa,"Resistant to oxacillin (100%), co-trimoxazole (100%), doxycycline (84.6%), ampicillin (92.3%), augmentin (23.1%), ceftazidime (12.8%). Exhibited multidrug resistance (SXTR DXTR CR AMPR ATMR).",Klebsiella pneumoniae,"Resistant to oxacillin (100%), co-trimoxazole (100%), chloramphenicol (95.5%), erythromycin (95.5%), ampicillin (95.5%), aztreonam (95.5%). Exhibited multidrug resistance (SXTR DXTR CR AMPR ATMR).","High resistance to third-generation cephalosporins (ceftazidime, ceftriaxone) and aminoglycosides observed in some isolates; all isolates resistant to oxacillin (indicative of MRSA)",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Widespread empiric use of broad-spectrum antibiotics; antibiotics sold without prescriptions by unauthorized persons; high misuse of antibiotics; lack of adherence to aseptic practices; shortage of qualified personnel; poor sterilization practices; lack of clean water in hospitals,Recommendations for regular surveillance of pathogens and their susceptibility patterns; strengthening infection control and drug dispensing policies; collaboration between microbiologists and clinicians; use of antimicrobial agents or drug combinations with wider spectra for prophylaxis or treatment; constant supply of potable water; consideration of natural products or non-antimicrobial methods for treatment,Did not evaluate anaerobic/fungal pathogens; did not determine minimum inhibitory concentrations; lack of comprehensive local data on wound infection and antibiotic susceptibility; urgent need for qualified nursing staff; gaps in infection control and surveillance,Hospital management boards and regional health authority had oversight; need for stronger infection control and drug dispensing policies identified; laboratory facilities for aerobic culture available but no mention of surveillance/reporting systems,Not Applicable,Not Applicable,Wound infections in healthcare settings are highly prevalent and frequently caused by multidrug resistant bacteria; infection control strategies and rational antibiotic use are urgently needed; regular surveillance and constant supply of clean water could reduce infection risk; collaboration between clinicians and microbiologists is essential to improve outcomes.,"Dates in abstract (October 2010 - March 2011) and results section (October 2009 - March 2010) differ; mean/median age, total procedures, and economic data not available; study focused on aerobic pathogens only; monomicrobial infections only identified."
"Kachipedzu Amos Tumizani, David King Kulapani, Samuel James Meja, Janelisa Musaya",2024,"Surgical site infection and antimicrobial use following caesarean section at QECH in Blantyre, Malawi: a prospective cohort study",Malawi,Prospective cohort,February 2023 - July 2023,"Queen Elizabeth Central Hospital (QECH), tertiary referral hospital",208,Pregnant women undergoing caesarean section,All women who underwent caesarean section procedure at QECH between 1st February 2023 and 31st July 2023,Women who underwent caesarean section in other health facilities,Mean 26.1 (SD 6.2) years; Range 15-42 years,100% female,Obstetrics & Gynecology,Caesarean section,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,208,20,9.61%,30-day clinical follow-up and microbiological wound culture using CDC criteria,5 (culture positive out of 10 tested specimens from 20 SSI cases),Staphylococcus aureus,"Resistant to clindamycin, erythromycin, gentamicin, and cefoxitin",Enterobacteriaceae,"Resistant to chloramphenicol and trimethoprim-sulfamethoxazole; sensitive to ciprofloxacin, meropenem, amikacin, and tigecycline; intermediate to gentamicin",Acinetobacter baumannii,"Resistant to ceftriaxone, ciprofloxacin, cefotaxime, and tigecycline; sensitive to gentamicin",Staphylococcus aureus resistant to cefoxitin (MRSA marker); Acinetobacter baumannii resistant to ceftriaxone and ciprofloxacin; Enterobacteriaceae sensitive to meropenem (not resistant),Not Applicable,Not Applicable,60%,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Inappropriate antimicrobial use (prolonged prophylaxis after surgery without microbiological confirmation), empiric use of broad-spectrum antibiotics, lack of routine culture before prescribing antibiotics","Recommendations for intensive infection prevention and control practices, establishment of antimicrobial stewardship (AMS) programs, and routine surveillance of SSIs at QECH","Limited microbiological data due to loss to follow-up, small sample size of isolates, restriction to CS cases only, need for further research on antimicrobial resistance patterns and drivers, lack of exploration of best approaches to address AMR",Need for AMS programs and routine surveillance highlighted; limited current laboratory data due to missed follow-up/culture,Not Applicable,Not Applicable,"Incidence of 9.61% SSI following CS at QECH is higher than in some other developing countries. Most patients received post-CS antibiotics without microbiological confirmation, promoting potential antimicrobial resistance. There is an urgent need for intensive infection control, AMS program establishment, and routine SSI surveillance.","Number of SSI cases determined both clinically (10) and by culture (10); only 5 cultures positive. No data on mortality, re-operation, length of stay, or economic burden. No explicit risk of bias tool mentioned. The study is limited to one hospital and to CS cases only."
"Hope Derick, Lucas Ampaire, Caesar Oyet, Enoch Muwanguzi, Hillary Twizerimana, Richard Onyuthi Apecu",2019,"Antimicrobial resistance in pathogenic aerobic bacteria causing surgical site infections in Mbarara regional referral hospital, Southwestern Uganda",Uganda,Descriptive cross-sectional,"June to August, 2015","Mbarara Regional Referral Hospital (MRRH), surgical, obstetrics/post-natal, gynecology, and orthopedics wards",83,Postoperative patients in study wards with clinical surgical site infection (SSI) within 30 days of operation,"Consented postoperative patients in surgical, obstetrics/post-natal, gynecology, and orthopedics wards presenting with clinical SSI within 30 days of operation",Not Applicable,Mean 26.51 ± 13.56 years (range 6-75 years),65.06%,"General Surgery, Obstetrics & Gynecology, Orthopedics","Caesarian section (C-section), surgical debridement, laparotomy, open reduction and internal fixation (ORIF), others",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,83,83,Not Applicable,Guidelines on prevention of SSI by CDC and protocol by European Centre for Disease Prevention and Control (ECDC); clinical diagnosis with bacteriological confirmation using wound swabs and standard microbiological techniques,93,Klebsiella species,"Ampicillin (100%), ceftriaxone (85.19%), sulfamethoxazole/trimethoprim (81.48%), gentamicin (81.48%), ciprofloxacin (55.56%); 100% MDR, 25.93% resistant to all antibiotics tested",Staphylococcus aureus,"Ampicillin (100%), oxacillin (100%), gentamicin (75%), ceftriaxone (90%), erythromycin (85%), sulfamethoxazole/trimethoprim (75%), ciprofloxacin (50%); 45% resistant to all antibiotics tested",Proteus species,"Ampicillin (100%), sulfamethoxazole/trimethoprim (90.91%), ceftriaxone (81.82%), gentamicin (81.82%), ciprofloxacin (63.64%); 18.18% resistant to one antibiotic, 36.36% resistant to five antibiotics",High resistance to ceftriaxone (3rd generation cephalosporin): Gram negative: 88.89%; Klebsiella: 85.19%; E. coli and Enterobacter spp: 100%,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Injudicious/irrational use of antibiotics (especially ampicillin); self-treatment with over-the-counter antibiotics; antibiotic misuse without evidence of causative agent and antibiogram; selection pressure in hospital environment,Recommendations for preoperative rectal swabs to detect colonization with MDR bacteria; periodic surveillance of SSI including aetiology and susceptibility profiling; strict adherence to infection control; guided therapy by susceptibility patterns,"Absence of data on anaerobic bacteria and fungi due to financial constraints; limited surveillance and notification systems; limited data on burden, aetiology, and susceptibility patterns of SSI in setting","Reference to lack of standardized diagnosis, absence of surveillance and notification systems in developing countries; Study recommends periodic SSI surveillance and laboratory-guided therapy",Not Applicable,Not Applicable,"SSI remains a major problem for postoperative patients; there is an alarming MDR rate of 86% among bacterial isolates and high resistance to commonly used antibiotics. Antibiotic therapy should be guided by susceptibility patterns. Periodic surveillance, infection control, and judicious antibiotic use are urged.","Incidence rate of SSI not reported for hospital admissions overall, only for those with clinical SSI; outcomes such as hospital stay, mortality, economic costs not provided. No explicit reporting of a risk of bias assessment."
"Odoko Desta, Abera Kumalo, Getachew Alemu, Tigistu Demisse, Teshale Mulugeta, Muluneh Temesgen",2024,Extended-spectrum ß-lactamase and carbapenemase producing Enterobacteriaceae among patients suspected with surgical site infection at Hospitals in Southern Ethiopia,Ethiopia,Hospital-based cross-sectional study,"June 1, 2022 - August 30, 2022","Two hospitals: Wolaita Sodo Comprehensive Specialized Hospital and Sodo Christian General Hospital, Sodo Town, Southern Ethiopia",422,Patients of all ages clinically suspected of having surgical site infection and admitted to two hospitals in Southern Ethiopia,"Patients clinically suspected of having surgical site infection (deep incisional, organ/space, and superficial incisional SSI as per CDC guidelines) during the study period",Not Applicable,"Median age group was 31-44 years (53.1% of sample), age range 5-96 years; SD/IQR Not Applicable",55.70%,"Orthopedics, General Surgery, Obstetrics & Gynecology",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"422 suspected, 100 culture-positive Enterobacterales infections (SSI definition per CDC criteria)",23.7% (100/422 patients with confirmed Enterobacterales infection),Clinical criteria per CDC guidelines; laboratory confirmation by culture of wound swabs/aspirates,"100 Enterobacterales isolates (69 Enterobacteriaceae, remainder Morganellaceae)",Escherichia coli,"Cefepime (90%), Ceftriaxone (93.2%), Ceftazidime (90%), Amoxicillin-clavulanic acid (96.6%), Ciprofloxacin (75.9%), Gentamicin (44.8%)",Klebsiella pneumoniae,"Cefepime (100%), Ceftriaxone (100%), Ceftazidime (100%), Amoxicillin-clavulanic acid (100%), Gentamicin (85.7%), Ciprofloxacin (78.6%), Meropenem (64.3%)",Klebsiella oxytoca,"Cefepime (87.5%), Ceftriaxone (87.5%), Ceftazidime (87.5%), Amoxicillin-clavulanic acid (100%), Gentamicin (87.5%), Ciprofloxacin (62.5%), Meropenem (25%)",Carbapenem (meropenem) resistance 27.9% overall among Enterobacteriaceae; carbapenemase-producing Enterobacteriaceae accounted for 15% of isolates; high resistance (>90%) to 3rd and 4th generation cephalosporins,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Patients with SSI due to ESBL/CPE had a higher length of stay; statistically significant association with SSI identified for hospital stay >8 days (AOR = 3.81, 95% CI 2.08-6.95), actual median/mean or days not specified",Not Applicable,Not Applicable,"Prolonged hospital stay, overuse of antibiotics, self-medication, prescribing antibiotics without susceptibility testing, absence of stewardship programs",Culture-based diagnosis and antimicrobial susceptibility testing (AST) for SSIs; recommendation for antibiotic selection based on culture and sensitivity results,"Lack of molecular testing for resistance mechanisms, resource constraints, limited generalizability from only two hospitals, lack of AMR surveillance and stewardship programs in Southern Ethiopia",AMR surveillance and stewardship described as lacking in study hospitals and region; no formal policies or infrastructure referenced,Not Applicable,Not Applicable,"High rates of ESBL and carbapenemase-producing Enterobacteriaceae are present in surgical site infections in Southern Ethiopia; prolonged hospital stay significantly increases risk; high levels of multidrug resistance and resistance to key antibiotics, particularly 3rd/4th generation cephalosporins; meropenem remains relatively effective but resistance is emerging; empirical therapy should be guided by culture and susceptibility testing; more research and stewardship interventions are urgently needed.","No data reported for surgical procedure types, re-operation, readmission, mortality, cost, or formal risk of bias assessment; microbiological and clinical data robust but some epidemiological rates (e.g., SSIs per procedure) not provided; multi-hospital design but regionally limited."
"Dinda Victor, Gunturu Revathi, Kariuki Sam, Hakeem Abdi, Raja Asad, Kimang'a Andrew",2013,"Pattern of Pathogens and their Sensitivity Isolated from Surgical Site Infections at the Aga Khan University Hospital, Nairobi, Kenya",Kenya,Prospective Cohort,March 2008 - May 2009,"Tertiary referral hospital (Aga Khan University Hospital, Nairobi)",268,Adult patients referred for general surgical procedures (excluding neurological and cardiothoracic surgeries),"Adult patients referred for surgery to Aga Khan University Hospital, Nairobi between March 2008 and May 2009 who had not undergone any surgical procedure in the previous one month","Patients referred for surgery out of disease complications being managed, those on multiple antimicrobial exposures due to chronic care prior to surgery, and all diagnostic surgical procedures",Mean age 38 years; Median age 37 years; (SD/IQR not specified),70.5% (189/268),General Surgery,General surgical procedures (excluding neurological and cardiothoracic surgeries); further detail not provided,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,268,39,7.0% (True SSI rate in clean and clean contaminated wounds); 14.6% overall infection rate post-surgery,Diagnosis by surgeon according to CDC definition; clinical assessment and laboratory confirmation (culture of pus swabs),29 (culture positive cases from SSIs),Staphylococcus aureus,"Ampicillin 60%, Doxycycline 40%, Azithromycin 30%, Augmentin 10%, Cefuroxime 10%, Ciprofloxacin 50%, Chloramphenicol 20%, Oxacillin 10%, Netilmicin 0%, Vancomycin 0%",Coagulase negative Staphylococcus,"Ampicillin 80%, Doxycycline 60%, Azithromycin 60%, Augmentin 40%, Cefuroxime 60%, Ciprofloxacin 20%, Chloramphenicol 40%, Oxacillin 0%, Netilmicin 0%, Vancomycin 0%","Klebsiella spp., E. coli, and Kluyvera spp. (each found in 12.8% of cases; grouped/third most common)","Klebsiella spp.: Cotrimoxazole 67%, Doxycycline 33%, Augmentin 67%, Cefotaxime 67%, Chloramphenicol 33%, Ciprofloxacin 0%, Gentamicin 67%, Cefuroxime 0%","Low MRSA prevalence (only 1 MRSA isolate); All Staphylococci susceptible to Vancomycin; Gram negatives show resistance to cefotaxime, cefuroxime, ciprofloxacin, and gentamicin; Imipenem resistance in P. aeruginosa (50%)",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Prolonged preoperative hospital stay, dirty wounds, prior antibiotic exposure (patients on multiple antimicrobial exposures prior to surgery excluded from study)","Antibiotic prophylaxis given according to institutional policy; Standard operating procedures for sample collection, transport, culture and susceptibility; Surveillance protocols described","Paucity of published reports on hospital pathogens and SSI risk factors in Kenyan hospitals; Lack of anaerobic culture system; SSI not stratified by depth (superficial, deep, organ space)","Laboratory is internationally accredited (ISO 15189:2007), participates in UKNEQAS; Institutional ethical approval obtained; Use of CDC definition for SSI",Not Applicable,Not Applicable,The SSI incidence rate (7.0%) observed in this study was relatively lower than documented in other Kenyan studies. Staphylococcus aureus is the most prevalent pathogen. Prolonged hospital stay and dirty wounds are the risk factors associated with postsurgical sepsis at the hospital.,"SSI case definition used CDC criteria, but SSIs were not stratified by depth. Sample size followed up through 1 month was 262 (6 lost to follow-up). Pathogen 3 includes several species with equal isolation frequency. Specific details of general surgical procedures are not specified."
"Gentilotti Elisa, Pasquale De Nardo, Boniface Nguhuni, Alessandro Piscini, Caroline Damian, Francesco Vairo, Zainab Chaula, Paola Mencarini, Peter Torokaa, Alimuddin Zumla, Emanuele Nicastri, Giuseppe Ippolito",2020,Implementing a combined infection prevention and control with antimicrobial stewardship joint program to prevent caesarean section surgical site infections and antimicrobial resistance: a Tanzanian tertiary hospital experience,Tanzania,Before-after intervention cohort study,"August 2013 - April 2015 (PRE-Int survey: 3 months from August 19, 2013; POST-Int survey: 3 months starting April 1, 2015; overall intervention period between surveys spans 2 years)",Dodoma Regional Referral Hospital (Tanzanian tertiary hospital); Obstetrics & Gynaecology Department,"1377 (664 pre-intervention, 713 post-intervention)",Women undergoing caesarean section,All consecutive women undergoing caesarean section at DRRH during designated 3-month PRE-Int and POST-Int survey periods,Not Applicable,"Not Available (only age categories reported: <20, 21-34, >34 years)",100%,Obstetrics & Gynaecology,Caesarean section,573 (follow-up available in POST-Int survey group),"Combined infection prevention and control measures with antimicrobial stewardship joint program, including formal and on-job training, evidence-based education on AMR, implementation of IPC protocols, AMS multidisciplinary team, pre-incision antibiotic prophylaxis (ampicillin 1g 30-60 min before incision), improvement of operating theatre discipline, optimized antibiotic prescription, standardized skin disinfection, absorbable continuous intradermic sutures",467 (follow-up available in PRE-Int survey group),"Usual care prior to intervention, consisting mainly of post-operative antibiotic courses (typically 8-10 days), variable timing of antibiotic administration, lower rates of prophylactic antibiotic use, less standardized skin disinfection and suture practice",Pre-incision antibiotic prophylaxis administered in 98% of patients post-intervention vs 2% pre-intervention; appropriate timing of prophylaxis achieved in 28% post-intervention,"1040 (patients with follow-up available: 467 pre-, 573 post-intervention)","320 (225 pre-intervention, 95 post-intervention)","48.2% pre-intervention, 16.6% post-intervention","CDC criteria, clinical wound examination by infectious diseases specialist, structured telephone interview; wound swab for culture in suspected cases","168 bacterial pathogens isolated from SSI wounds (106 pre-intervention, 62 post-intervention)",Staphylococcus aureus,"MRSA prevalence: 79% of S. aureus pre-intervention, 21.4% post-intervention; all post-intervention MRSA isolates showed inducible resistance to clindamycin; susceptibility: 43.2% to tetracycline, 13.5% to chloramphenicol, 5.4% to cotrimoxazole (post-intervention)",Coagulase-negative Staphylococcus species,Not Applicable,Klebsiella spp.,"Pre-intervention: 100% Klebsiella spp. isolates were MDROs; post-intervention: 42.8% MDROs (resistant to amoxicillin/clavulanate, ceftriaxone, gentamicin and/or ciprofloxacin)",No resistance to vancomycin and meropenem observed in POST-Int group; high rates of MDR gram-negative organisms (over half of all isolates); 80% of Enterococcus spp. resistant to ampicillin; no detailed rates for 3rd gen cephalosporins/carbapenems beyond above,Not Applicable (mean days of hospitalization for all groups was approximately 2 days),Not Applicable,Not Applicable,Not Applicable,"Not Applicable (2 deaths before discharge reported in pre-intervention group, but not attributed directly to SSI)",Not Applicable,Approximately 2 days (mean) reported for both groups; not stratified by SSI,Estimated hospital cost savings of €1500 during post-intervention (by switching from 3 days IV antibiotics post-op to single-dose pre-op prophylaxis),Estimated personal saving of €3 per patient due to reduction in post-discharge antibiotic prescriptions,"Widespread use of post-operative antibiotics, lack of local AMR surveillance systems, inappropriate antibiotic prescribing practice, supply chain limitations for antibiotics and laboratory disposables","Hospital-based multidisciplinary IPC-AMS program, literature-based education, scheduled seminars, on-job training, prioritized prevention measures, strengthened supply chain for antibiotics/disinfectants/disposables, established AMS team and improved laboratory capability (WHO SLIPTA 3-star accreditation)","Need for efficient national AMR surveillance system, data on MDROs prevalence in Tanzania lacking, study design limitations (not able to isolate effect of individual intervention components or analyze impact of comorbidities such as diabetes or hypertension); require further robust studies","DRRH laboratory improved and achieved WHO AFRO SLIPTA 'three star' recognition; study supported by hospital management and Tanzanian National Institute for Medical Research; however, broader national/regional surveillance still limited",Not Applicable,Not Applicable,"A combined infection prevention and control with antimicrobial stewardship program led to a substantial reduction in caesarean section SSI rates (more than 65% reduction) and MRSA prevalence at a Tanzanian tertiary hospital. Improved IPC and AMS education for hospital staff is essential, and improved SSI/AMR surveillance is warranted. The multidisciplinary approach is effective, but robust multicenter studies are needed to further inform best practice.","Some values (e.g., age Mean/SD, re-operation rate, readmission rate, mortality directly attributable to SSI) not reported; total sample size differs depending on analytic denominator (all enrolled vs. patients with follow-up); pathogen resistance percentages sometimes calculated from subgroup n rather than all isolates."
"Gemedo Misha, Legese Chelkeba, Tsegaye Melaku",2021,Bacterial profile and antimicrobial susceptibility patterns of isolates among patients diagnosed with surgical site infection at a tertiary teaching hospital in Ethiopia: a prospective cohort study,Ethiopia,Prospective cohort study,"April 20 to August 20, 2019",Tertiary teaching and referral hospital (Jimma Medical Center),251,"Adult patients (age ≥18 years) who underwent elective or emergency surgical procedures at general surgery, gynecology/obstetric, and orthopedics wards",Adult patients (age ≥18 years) who underwent either elective or emergency surgical procedures at JMC; followed for 30 days post-op for SSI occurrence,"Patients initially diagnosed with SSIs, died within 48 hours, or refused to participate",Mean 38 (SD 16.3) years,50.20%,"General Surgery, Orthopedics, Gynecology and Obstetrics",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,251,53,21.10%,Clinical assessment by attending physician using CDC SSI surveillance methods and criteria,38,Escherichia coli,"Cefepime 100%, ceftriaxone 55%, cefuroxime 55%, cotrimoxazole 22%, ciprofloxacin 55%, ampicillin 44%. Meropenem 0% resistance (100% effective)",Pseudomonas aeruginosa,"Cefepime 100%, ceftriaxone 100%, meropenem 62.5%, ceftazidime 62.5%, ciprofloxacin 50%, gentamicin 50%",Proteus species,"Cefepime 100%, cefuroxime 100%, ceftriaxone 100%, ciprofloxacin 67%, ampicillin 67%, cotrimoxazole 67%, chloramphenicol 67%","High resistance reported to ceftriaxone (78.79%), cefepime (87.88%); meropenem resistance seen only in Pseudomonas (62.5%), but E. coli 0% resistance to meropenem",SSI doubles the duration of hospital stay (no specific number of days),Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Extra costs due to SSI of between 800 and £ 7000 have been recorded (citation from literature, not new data)",Not Applicable,"Indiscriminate use of antibiotics, especially ceftriaxone as prophylaxis, and empirical prescribing",Strengthening antimicrobial stewardship programs and periodic antimicrobial resistance surveillance recommended; emphasis on routine microbial analysis of samples and antibiogram,"Lack of multi-center studies, limitations in laboratory capacity (no anaerobic cultures), need for antimicrobial resistance surveillance and antibiotic stewardship",Hospital protocol for management of SSI; limitations in microbiology laboratory capacity noted (no anaerobic culture),Not Applicable,Not Applicable,"Gram-negative bacteria, particularly Escherichia coli, were the most common isolates from surgical sites; high rates of antibiotic resistance were observed, highlighting the necessity for routine microbial analysis and stewardship interventions; multi-center and surveillance studies are needed.","Anaerobic bacteria not analyzed due to laboratory limitations. No procedure-specific data, morbidity or mortality outcomes reported. Economic figures quoted from prior studies, not this cohort. No formal risk of bias tool used or described."
"Haitham Hamudu, Helmut Nyawale, Vitus Silago, Mariam M. Mirambo, Phillipo L. Chalya, Stephen E. Mshana",2025,"Incidence, bacteriological profile and predictors of surgical site infections following limb amputation at Bugando medical centre and Sekou toure referral regional hospital, Mwanza, Tanzania",Tanzania,Longitudinal,March - July 2024,Bugando Medical Centre (tertiary referral hospital) and Sekou Toure Regional Referral Hospital (public regional facility),120,Patients undergoing limb amputations,All consenting patients who underwent limb amputation at Bugando Medical Centre and Sekou Toure Regional Referral Hospital between March and July 2024,Patients who previously undergone amputation in other healthcare facilities who were referred for stump revisions,Median 58 [IQR 43.5-66.5] years,46.70%,"General Surgery, Pediatric Surgery, Plastic Surgery, Orthopedic Surgery",Limb amputation (upper and lower limb; closed and open amputation),Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,120,36,30%,CDC criteria with clinical assessment and wound/pus swab for culture,30,Escherichia coli,"Ampicillin 86.7%, trimethoprim/sulphamethoxazole 80%, ceftriaxone 80%, ceftazidime 73.3%, gentamicin 73.33%, ciprofloxacin 60%, cefepime 60%, ceftriaxone/sulbactam 66.7%, amikacin 33.3%, piperacillin/tazobactam 53.3%; 0% resistance to meropenem",Staphylococcus aureus,"Ampicillin 57.14%, trimethoprim/sulphamethoxazole 57.14%, gentamicin 14.29%, ciprofloxacin 28.57%, amikacin 14.29%, vancomycin 0%, ceftriaxone not tested (NA)",Pseudomonas aeruginosa,"Ampicillin 75%, trimethoprim/sulphamethoxazole 75%, cefepime 0%, ceftazidime 25%, ceftriaxone 50%, ceftriaxone/sulbactam 75%, gentamycin 25%, amikacin 25%, piperacillin/tazobactam 50%; 0% resistance to meropenem",More than half of Gram-negative isolates were resistant to third and fourth generation cephalosporins; all Enterobacterales and non-fermenters sensitive to meropenem,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Transmission from health care environment; high use of third and fourth generation cephalosporins for prophylaxis,Recommendation to update antibiotic prophylaxis protocols tailored to local surveillance data; strengthen antimicrobial stewardship and infection prevention and control (IPC) programs,"Limited data on anaerobic bacteria due to lack of anaerobic cultures; superficial swab cultures may not always represent organisms causing deep wound infections; lack of reporting of resistance mechanism proportions in gram negatives (e.g. ampC, ESBL) and Gram-positives (MRSA); need for improved IPC and antibiotic stewardship",Mention of need to strengthen antimicrobial stewardship and infection prevention programs and tailor antibiotic protocols to local surveillance,Not Applicable,Not Applicable,"About one third of patients developed SSIs after limb amputation, with increased odds in younger age, smokers, higher ASA score, prolonged surgery, and blood transfusion. The predominance of multidrug resistant Gram-negative bacteria highlights urgent need to strengthen antimicrobial stewardship and IPC programs and to update management protocols based on local surveillance data.","No major ambiguities, but data on economic burden, length of stay, reoperation or readmission rates, and mortality attributable to SSI is missing/not reported."
"Ojulong Julius, T.P. Mwambu, M. Joloba, F. Bwanga, D.H. Kaddu-Mulindwa",2009,"Relative prevalence of methicilline resistant Staphylococcus aureus and its susceptibility pattern in Mulago Hospital, Kampala, Uganda",Uganda,Cross-sectional laboratory-based study,February to May 2007,"Mulago National Hospital (Tertiary referral, teaching and research hospital)",188,"Patients with surgical site infections from Surgical, Obstetrics, and Gynecology wards",Patients with surgical site infections yielding pus swabs for culture,Not Applicable,Not Applicable,Not Applicable,"General Surgery, Obstetrics & Gynecology",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,188 (patients with surgical site infections swabbed),Not Applicable,Clinical diagnosis with collection of pus swabs for microbiological identification,54 S. aureus isolates (from 188 SSI specimens); 17 MRSA isolates,Staphylococcus aureus,"MRSA resistance rates: 88.2% trimethoprim-sulfamethoxazole, 88.2% erythromycin, 58.8% gentamycin, 70.6% ciprofloxacin, 88.2% chloramphenicol, 100% penicillin, 0% vancomycin, 0% clindamycin (but 82.4% inducible resistance shown by D-test)",Not Applicable,Not Applicable,Not Applicable,Not Applicable,All MRSA isolates were susceptible to vancomycin (a WHO critically important antibiotic); 70.6% resistance to ciprofloxacin; 58.8% resistance to gentamycin,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"High cost and unavailability of alternative antibiotics (e.g., vancomycin) noted as an economic treatment consideration",Not Applicable,"Broad-spectrum antibiotic use, cross resistance among antibiotics, transmission via hand contamination, drug pressure in the community",Recommendation to perform routine D-test for inducible clindamycin resistance; highlight need for accurate laboratory detection and guided chemotherapy,Lack of routine D-test for inducible clindamycin resistance; absence of large-scale studies of MRSA susceptibility in the East African region; limited access to alternative antibiotics,Laboratory capacity to detect MRSA and perform susceptibility testing present at Makerere University; need for larger surveillance studies identified,Not Applicable,Not Applicable,High prevalence of multidrug-resistant MRSA among S. aureus isolates from surgical site infections. Vancomycin is currently the only consistently effective antimicrobial agent against MRSA in this setting. Routine D-test for inducible clindamycin resistance should be performed. Large studies across East Africa are needed to guide therapy.,"The study did not provide data on age or sex distribution, clinical morbidity outcomes, economic indirect costs, or other SSI pathogens. SSI rates per procedure and patient outcomes are not addressed. All data are based on microbiological analysis of surgical site infection swabs, not patient-level outcomes."
"Iyamba Jean-Marie Liesse, José Mulwahali Wambale, Cyprien Mbundu Lukukula, Ntondo za Balega Takaisi-Kikuni",2014,High prevalence of methicillin resistant staphylococci strains isolated from surgical site infections in Kinshasa,Democratic Republic of Congo,Laboratory-based cross-sectional study,January to October 2013,"Provincial General Reference Hospital of Kinshasa (HGPRK) and Clinic of University of Kinshasa (CUK), tertiary hospital structure",130,Hospitalized surgical patients with purulent lesions of infected surgical sites,Hospitalized surgical patients with infected sites and purulent lesions,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,130,Not Applicable,Wound swab collection from purulent infected sites; laboratory identification of staphylococcal strains using standard microbiological methods and latex agglutination test,"89 staphylococcal isolates (74 S. aureus, 15 CNS)",Staphylococcus aureus,"MRSA: 89.4% ampicillin, 76.6% cotrimoxazole, 76.6% erythromycin, 68% clindamycin, 57.4% ciprofloxacin, 57.4% cefotaxime, 53% ceftazidime; 19% vancomycin",Coagulase-negative staphylococci (CNS),"MR-CNS: 88.9% ampicillin, 100% cotrimoxazole, 77.8% erythromycin, 66.7% clindamycin, 100% ciprofloxacin, 66.7% cefotaxime, 44.6% ceftazidime",Not Applicable,Not Applicable,"All MRSA and MR-CNS strains were sensitive to imipenem (carbapenem) and most to vancomycin (19% MRSA resistant), multidrug resistance present",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,High-pressure use of broad-spectrum antibiotics and long hospital stays,Authors recommend antibiotic susceptibility testing prior to treatment; surveillance policy suggested as national priority,Lack of antibiotic surveillance policies and genomic characterization of S. aureus strains; limited data on MR-CNS prevalence,No national antibiotic surveillance policy in DRC,Not Applicable,Not Applicable,"High prevalence of multidrug resistant MRSA and MR-CNS strains isolated from SSIs; imipenem, amoxicillin-clavulanic acid, and vancomycin are the most active antibiotics; antibiotic surveillance policy should become national priority.","No data provided on age, sex, surgical specialty, specific procedures, or clinical outcomes. All SSI cases defined by positive wound culture; ambiguity in counting total SSIs versus total staphylococcal isolates."
"Manyahi Joel, Mecky I Matee, Mtebe Majigo, Sabrina Moyo, Stephen E Mshana, Eligius F Lyamuya",2014,"Predominance of multi-drug resistant bacterial pathogens causing surgical site infections in Muhimbili national hospital, Tanzania",Tanzania,Descriptive cross sectional,September 2011 - February 2012,"Muhimbili National Hospital (MNH), tertiary referral teaching hospital",100,"Patients aged 18-80 years with clinical evidence of surgical site infection from general surgery, obstetrics and gynecology, and orthopedic wards",Patients with clinical evidence of SSI as defined by CDC,Not Applicable,Range 18-80 years; Mean/SD not specified,47%,"General Surgery, Obstetrics & Gynecology, Orthopedics","Surgical debridement and external fixation (27%), laparotomy (25%), caesarean section (15%)",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,100,Not Applicable,Clinical evidence as defined by CDC criteria,147,Pseudomonas aeruginosa,"Resistant to ceftazidime (88%), gentamicin (8%), ciprofloxacin (8%), tetracycline (NA), meropenem (0%)",Staphylococcus aureus,"Penicillin (83%), ampicillin (92%), amoxycillin/clavulanic acid (73%), ceftriaxone (47%), gentamicin (33%), ciprofloxacin (29%), clindamycin (6%), erythromycin (39%), tetracycline (35%), co-trimoxazole (20%), chloramphenicol (47%)",Klebsiella pneumoniae,"Ampicillin (100%), amoxycillin/clavulanic acid (94%), ceftriaxone (81%), ceftazidime (88%), cefotaxime (88%), gentamicin (67%), ciprofloxacin (56%), tetracycline (56%), co-trimoxazole (94%), chloramphenicol (54%), meropenem (0%)","High resistance (67-100%) to 3rd generation cephalosporins (ceftriaxone, ceftazidime, cefotaxime) among Gram negative bacteria; All tested Gram negative isolates susceptible to meropenem; ESBL producers noted in E. coli (92.3%) and K. pneumoniae (69%)",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Prolonged hospital stay noted qualitatively, quantitative data not provided",Not Applicable,Not Applicable,"Inappropriate use of antimicrobial agents, high antimicrobial exposure (95% documented antimicrobial use within a month, 80% received ceftriaxone prophylaxis)",Recommendation for urgent revision of perioperative antimicrobial prophylaxis policy at national referral hospital,Cross-sectional design; lack of 30-day post-discharge follow up; need for standardized guidelines for antibiotic use and SSI management,Need for significant change in antibiotic prescription policy; current lack of standardized perioperative antimicrobial policy noted,Not Applicable,Not Applicable,"A high proportion of isolates (63%) causing SSIs were multidrug resistant, with 90% resistant to more than four classes of antibiotics; urgent revision of antibiotic policy is needed for rational and effective SSI management in the hospital.",No SSI incidence rate given; cross-sectional design and lack of post-discharge follow-up limit findings; sex breakdown unclear if 53% male/47% female or vice versa; sample size matches throughout; most data on resistance provided as percentages;
"Boru Kalicha, Alqeer Aliyo, Derese Daka, Tibeso Gamachu, Oliyad Husen, Zekarias Solomon",2025,"Bacterial surgical site infections: prevalence, antimicrobial susceptibility patterns, and associated risk factors among patients at Bule Hora University Teaching Hospital, Southern Ethiopia",Ethiopia,Cross-sectional study,1 January – 30 June 2023,Bule Hora University Teaching Hospital (tertiary-level public hospital),183,Patients who underwent surgical treatment during the study period and exhibited signs of surgical site infection,"All patients with signs of SSI, based on criteria stated by WHO and CDC during the data collection period","Patients with incomplete charts, those who underwent surgery at another institution, and those with nonoperative wounds or abscesses",31.65 (SD 19.357) years; range 1–95 years,44.8% female (n=82),Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,29,"15.8% (95% CI, 10.9–22)","Clinical assessment by physician; features including pain, redness, swelling, discharge, fever; followed CDC (and WHO) criteria; culture confirmation",41,Staphylococcus aureus,"Penicillin (78.6%), ceftazidime (78.6%), cefoxitin (57.1%, indicating MRSA), amoxicillin (35.7%)",Coagulase-negative staphylococci,"Penicillin (71.4%), ceftazidime (57.1%)",Escherichia coli,"Ampicillin (83.3%), ceftazidime (83.3%), amoxicillin (66.7%), penicillin (66.7%)",8/14 S. aureus isolates (57.1%) resistant to cefoxitin (MRSA); high resistance to 3rd generation cephalosporins in E. coli and other Gram-negatives,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Loss of daily wages mentioned as an impact but no quantitative data provided,"Frequent and inappropriate use of antimicrobial agents, self-medication practices, antibiotics are easily obtainable and used without a prescription","Recommendation to establish a functional microbiology laboratory, review infection prevention practices, and limit the use of certain antibiotics","Need for routine screening and antimicrobial susceptibility testing, need for studies including fungi and anaerobic bacteria, call for nationwide survey of SSIs and antimicrobial resistance","Patients with SSI received care according to national standards; recommendation for improved laboratory infrastructure, routine surveillance, and infection prevention",Not Applicable,Not Applicable,"High prevalence of SSIs and multidrug-resistant isolates compared to WHO or previous studies. Routine screening and susceptibility testing are needed. Significant risk factors include older age, longer hospital stay, extended operative times, and malnutrition.",No specific breakdown by surgical specialty or procedure; no economic cost quantification; no hospital stay or morbidity/mortality outcomes reported.
"Velin Lotta, Theoneste Nkurunziza, Grace Umutesi, Gilbert Rukundo, Robert Riviello, Jean De Dieu Gatete, Moses Muwanguzi, Ivan Emil, Lisa M. Bebell, Bethany L. Hedt-Gauthier, Marthe Yankurije, Fredrick Kateera, Kara Faktor",2021,Surgical Site Infections and Antimicrobial Resistance After Cesarean Section Delivery in Rural Rwanda,Rwanda,Prospective cohort study,"September 23, 2019 - March 16, 2020",Kirehe District Hospital (Governmental hospital supported by Partners In Health-Rwanda),795,Women who underwent cesarean deliveries at a rural Rwandan district hospital,"Women who delivered via cesarean section at Kirehe District Hospital between September 23, 2019, and March 16, 2020 and for whom study-related follow-up was feasible, before COVID-19 distancing policies were implemented",Women from Mahama Refugee Camp were excluded due to inability to complete study activities; Women unable to be followed up before COVID-19 restrictions,Not Applicable,100%,Obstetrics & Gynecology,Cesarean section delivery,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,795,45,5.70%,Clinical diagnosis by trained GPs using CDC guidelines; confirmed by wound examination at POD 11 (+/- 3 days),57,Coagulase-negative staphylococci (CoNS),"Penicillin (100% resistant), cefoxitin (71% resistant), TMP-SMX (82% resistant), clindamycin (55% resistant), tetracycline (55% resistant), levofloxacin (29% resistant)",Acinetobacter baumannii complex,"Ceftriaxone (100% resistant), cefepime (78% resistant), gentamicin (56% resistant), tetracycline (56% resistant), TMP-SMX (67% resistant), imipenem (11% intermediate/resistant)",Proteus species,"Ampicillin (100% resistant), ceftriaxone (88% resistant), cefepime (88% resistant), gentamicin (13% resistant), amikacin (63% resistant), ciprofloxacin (63% resistant), levofloxacin (67% resistant), piperacillin-tazobactam (25% resistant), TMP-SMX (63% resistant), imipenem (38% resistant)","All gram-negative pathogens showed high levels of resistance or intermediate susceptibility to ceftriaxone (92.1%) and cefepime (84.6%). All isolates tested were resistant to cefazolin and aztreonam. All Acinetobacter, Klebsiella, Proteus, and Enterobacter cloacae isolates demonstrated non-susceptibility to imipenem.",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Misuse and overuse of antibiotics, frequent use of ampicillin pre- and post-operatively, empiric prescription based on availability and provider preference, inconsistent adherence to WHO guidelines",Training of general practitioners in CDC SSI diagnosis; use of Levine technique for swab collection; attempted adjustment of treatment based on microbiology results,Need for research on risk factors contributing to high prevalence of gram-negative and resistant pathogens; lack of effective treatment options due to increasing resistance; lack of evidence-based protocols for rational use of antibiotics at district hospitals; limitations of wound cultures and microbiology in resource-limited settings; limited adherence to guidelines on antibiotic prophylaxis,"Samples processed by Rwanda National Reference Laboratory, but resource constraints identified; challenges in procurement of standard laboratory media",Not Applicable,Not Applicable,"Bacterial isolates from SSI swab cultures in rural Rwanda predominantly consisted of gram-negative pathogens and were largely resistant to commonly used antibiotics. This raises concerns about the effectiveness of antibiotics currently used for surgical prophylaxis and treatment, and may guide appropriate selection of treatment of SSIs in rural Rwanda and comparable settings. Additional research is needed to determine risk factors contributing to the high prevalence of gram-negative and resistant pathogens.",Mean/median age and measures of additional morbidity/mortality are not reported. No formal risk of bias tool is mentioned. Adherence to guidelines is only discussed narratively; no percentage given. The sample size for antibiotic resistance results sometimes varies due to the addition of antibiotics to testing panel after the study began.
"Mengesha RE, Kasa BG, Saravanan M, Berhe DF, Wasihun AG",2014,"Aerobic bacteria in post surgical wound infections and pattern of their antimicrobial susceptibility in Ayder Teaching and Referral Hospital, Mekelle, Ethiopia",Ethiopia,Prospective cross-sectional study,January to June 2012,Ayder Teaching and Referral Hospital (tertiary referral hospital),128,"Patients post-surgery in general surgery and orthopedic wards, with clinical signs of post surgical wound infection",Patients who had undergone surgery in the hospital and developed SSI as diagnosed clinically by physicians within 30 days of post surgical procedure,"Surgical patients with community-acquired pyogenic infections (abscess, furuncle, carbuncles); patients with infection of episiotomy; patients with open fractures",Mean 35.95 ± 19.01 years,30/128 (23.4%),"General Surgery, Orthopedics",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,610 (during study period); 128 developed clinical SSI and included,128 (inclusion: all had clinical SSI),"Not specified as % among all operated, but 128/610 (21%) developed clinically-diagnosed SSI; and 75% (96/128) of suspected SSIs were culture-positive","Clinical diagnosis by physicians (symptoms of infection), with confirmation by wound swab aerobic culture",123,Staphylococcus aureus,"90% resistance to Tetracycline, Ceftriazone, Ampicillin; 85% resistance to Cloxacilline; 100% sensitive to Vancomycin",Klebsiella spp.,100% resistant to Amoxicillin; 93.1% resistance to Tetracycline; 89.7% resistance to Ampicillin; 86.2% resistance to Ceftriazone; 27.8% resistance to Gentamicin,Coagulase negative Staphylococci (CoNS),88.9% resistance to Amoxicillin; 77.8% resistance to Amoxicillin-clavunilic acid; 77.8% resistance to Ampicillin; 77.8% resistance to Tetracycline; 100% sensitive to Vancomycin,"High resistance to third generation cephalosporin (Ceftriazone) seen in Klebsiella spp. (86.2%), P. aeruginosa (100%), S. aureus (90%)",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Indiscriminate use and easy availability of antibiotics without proper prescription; irrational prescriptions,Periodic surveillance of bacteria and antibiotic susceptibility recommended by authors to prevent further emergence and spread of resistant pathogens,Scarcity of local/regional surveillance data on SSI pathogens and resistance; inability to isolate anaerobic bacteria and fungi; lack of standardization of SSI diagnostic criteria,Not Applicable,Not Applicable,Not Applicable,Surgical site wound infection rate was high (75%) and multidrug-resistance was seen in 82.92% of isolates. Periodic surveillance of bacteria and antibiotic susceptibility is needed to prevent emergence and spread of resistant pathogens.,"The sample size in the results (128) matches methods. SSI incidence is only among clinically suspected cases (not all operations), so 21% SSI by clinical diagnosis in all surgical patients during the study period but not rigorously reported as SSI incidence rate among all surgeries. No outcome/morbidity/mortality data provided."
"Scherbaum Micha, Katrin Kösters, Raymund Egid Mürbeth, Ulysse Ateba Ngoa, Peter Gottfried Kremsner, Bertrand Lell, Abraham Alabi",2014,"Incidence, pathogens and resistance patterns of nosocomial infections at a rural hospital in Gabon",Gabon,Prospective surveillance study,January to July 2009,"Albert Schweitzer Hospital, rural tertiary regional hospital",2925,"Patients admitted to the departments of surgery, gynecology/obstetrics and internal medicine","All patients admitted to study departments and screened daily for signs and symptoms of nosocomial infections; further evaluation for patients with new occurrence of fever (>38°C) at least 48 hours after admission, repeated fever after a non-febrile interval of 72 hours, signs of surgical site infection, or reopening of the operation site due to infection",Not Applicable,Median 30 (IQR 22-42) years for all patients; Median 41 (IQR 33-69) years for patients with nosocomial infections,65%,"General Surgery, Obstetrics & Gynecology","abdominal hysterectomy, caesarean section, appendectomy, myomectomy, salpingectomy (ectopic pregnancy), herniotomy",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,1059,20,1.9% (95% CI 1.1 - 2.7%) per operation,Clinical assessment with microbiological confirmation where possible; classification based on Robert Koch Institute definitions as per CDC guidelines,"Not directly stated; most frequent pathogen in SSI: S. aureus (9 isolates in SSI); total Gram-positive and Gram-negative bacteria: 36 and 34, respectively",Staphylococcus aureus,0/14 sensitive to penicillin; 14/14 sensitive to cloxacillin,Escherichia coli,1/14 (7%) sensitive to ampicillin; 6/14 sensitive to amoxicillin-clavulanic acid; 9/14 (64%) sensitive to ceftriaxone; 9/14 (64%) sensitive to gentamicin; 9/14 (64%) sensitive to ciprofloxacin; 3/12 sensitive to cotrimoxazole; 5/14 (36%) ESBL producers,Enterococcus spp.,0/9 sensitive to penicillin; 9/9 sensitive to ampicillin,"E. coli: Only 64% sensitive to ceftriaxone (a 3rd gen cephalosporin); K. pneumoniae: Only 50% sensitive to ceftriaxone, ciprofloxacin and gentamicin; ESBL production noted in E. coli (36%) and K. pneumoniae (50%)","Patients with nosocomial infections stayed a mean of 27 days (range 4-108), which is 23 days longer than the average patient",Not Applicable,Not Applicable,Not Available specifically for SSI; but 11% of patients with nosocomial infections died,Not Applicable,Not Applicable,Mean stay for nosocomial infection patients: 27 days (range: 4-108); Median 22 (IQR 13-34) days,Not Applicable,Not Applicable,High use of antibiotics in the hospital and as outpatients; antibiotics freely available over the counter; inappropriate use of anti-infectious medications including routine long duration prophylaxis,"Recommendations for infection control interventions, improved perioperative prophylaxis, antibiotic stewardship measures, quality management, and personnel capacity building",Lack of microbiological laboratory infrastructure in small rural hospitals; lack of regional surveillance data; inability to detect post-discharge infections; limited treatment options for ESBL pathogens; need for sound surveillance and competent microbiology,"Microbiological lab available at facility, but no effective antibiotics for ESBL strains; surveillance recommended as mandatory; need for capacity building highlighted",Not Applicable,Not Applicable,"High rates of surgical site infections and multi-resistant pathogens necessitate urgent comprehensive infection control interventions. The overall incidence of nosocomial infections was low, but higher rates were seen after gynecological operations. Surveillance and improved use of antibiotics are needed. Many Gram-negative bacteria display resistance to commonly prescribed antibiotics, and antibiotics for ESBL strains are not available.",No direct SSI mortality is reported; some granularity is lost in data on pathogen isolates for SSI specifically; ESBL rates are pooled for E. coli and Klebsiella across infection types.
"NIHR Global Health Research Unit on Global Surgery, Dr Shereen Rachel Varghese, Dr Elizabeth Li",2024,"Microbiology testing capacity and antimicrobial drug resistance in surgical-site infections: a post-hoc, prospective, secondary analysis of the FALCON randomised trial in seven low-income and middle-income countries","Benin, Ghana, Nigeria, Rwanda, South Africa (ECSA countries only; also India and Mexico were included in the overarching trial)",Post-hoc prospective secondary analysis of a Randomised Controlled Trial,"December 10, 2018 - September 7, 2020",54 hospitals (multiple tertiary and district hospitals) in seven countries,5788 (FALCON trial); 1163 with SSI included in this analysis,Patients undergoing abdominal surgery with an incision of 5 cm or greater,"All eligible, consecutive patients undergoing abdominal surgery with incision ≥5 cm; stratified by intraoperative contamination level; patients with SSI diagnosed by CDC criteria included in this analysis",Patients undergoing clean operations (gastrointestinal tract not entered); patients without SSI for this sub-analysis,Mean 35.6 years (SD 18.3) for SSI patients,57.6% female among SSI patients,"General Surgery (abdominal surgery); also includes subgroups such as obstetric, trauma, malignant, and benign abdominal surgery",Abdominal surgery with incision ≥5 cm; further breakdown not provided,266 alcoholic chlorhexidine + triclosan-coated suture; 286 alcoholic chlorhexidine + non-coated suture; 300 povidone-iodine + triclosan-coated suture; 284 povidone-iodine + non-coated suture (within SSI cohort),Randomised to 2% alcoholic chlorhexidine or 10% aqueous povidone-iodine skin preparation and either triclosan-coated or non-coated sutures,N/A (all groups received active interventions; analysis is on SSI subgroup across all trial arms),Not Applicable,Not directly reported; regular infection control teams in 21-44% of hospitals; overall guideline adherence not quantified,5788 (full trial); 1163 with SSI,1163,"22.0% (1163 of 5284, 95% CI 20.9–23.2) among eligible trial patients",CDC criteria for surgical-site infection,235 (from 228 patients swabbed),Escherichia coli,"64% AMR reported in meta-analysis; 69.4% MDR among all isolates with MDR data; specific rates for E. coli not extracted in primary article but overall high resistance to 3rd-gen cephalosporins (48.1%), 2nd-gen cephalosporins (77.4%), fluoroquinolones (42.2%), antipseudomonal penicillins (43.1%)",Klebsiella spp.,"Up to 85% AMR to 3rd-gen cephalosporins (meta-analysis), 51.1% MDR overall in isolates",Staphylococcus aureus,48% methicillin resistance (meta-analysis); specific in-study resistance rates not disaggregated,"High resistance to 3rd-generation cephalosporins (48.1%), carbapenems tested but not quantified; gentamicin susceptibility 17.8%, fluoroquinolones susceptibility 11.2%, chloramphenicol best at 24.2%",Not Applicable,11.5% (131/1138 with SSI),12.0% (136/1138 with SSI),2.5% (29/1163 with SSI) died (attributable specifically to SSI not detailed),2.5% in SSI cohort,Not Applicable,Not Applicable,Not Applicable,Catastrophic health expenditure for patients and families discussed but not quantified,"Inappropriate antimicrobial use, poor infection prevention and control practices, limited access to microbiology diagnostics, overuse and misuse of antimicrobials, widespread lack of local guidelines","Implementation of infection control teams, development of local guidelines, use of targeted perioperative antibiotic prophylaxis, expansion of testing capacity; reference to ChEETAh trial (glove/instrument change before wound closure)","Limited microbiology testing capacity, lack of local guidelines on antimicrobial prophylaxis, insufficient infection control teams, inadequate surveillance and laboratory infrastructure","Reference to Fleming Fund (UK) supporting AMR surveillance capacity; Africa CDC identifying AMR as urgent public health threat; hospitals surveyed for capacity, routine screening for ESBL, MRSA, VRE, and CPE was variable",STROBE checklist (used for reporting); study protocol referenced,"Not directly reported; limitations include inability to classify MDR in all microorganisms, post-hoc analysis, missing reasons for lack of wound swabs","Systemic weaknesses exist in the testing capacity and prevention of MDR in LMIC hospitals. These weaknesses are associated with non-targeted antibiotic use and high levels of AMR. Expansion of testing capacity, local guideline development, and implementation of infection control teams could reduce the burden of MDR in SSIs.","Sample size and subgroup numbers are complex; numbers in some trial arms may differ due to exclusions and missing data. Data on direct/indirect costs and detailed procedure types were not reported. Pathogen-specific resistance rates are mostly from referenced meta-analysis, not this study's primary data."
"De Nardo P, E. Gentilotti, B. Nguhuni, F. Vairo, Z. Chaula, E. Nicastri, M.M. Nassoro, N. Bevilacqua, A. Ismail, A. Savoldi, A. Zumla, G. Ippolito",2016,Post-caesarean section surgical site infections at a Tanzanian tertiary hospital: a prospective observational study,Tanzania,Prospective observational cohort study,"August 19, 2013 - approximately November 19, 2013","Dodoma Regional Referral Hospital (DRRH), Gynaecology and Obstetrics Department, tertiary referral hospital",467,Pregnant women who underwent elective or emergency caesarean section,All pregnant women admitted to the DRRH Labour Ward who underwent an elective or emergency caesarean section and were enrolled within 24 h post CS,Not attending any clinical visit after CS and failed telephone contact (197 out of initial 664 lost to follow-up),Not Applicable,100%,Obstetrics & Gynecology,Caesarean section (midline vertical and Pfannestiel incisions),Not Applicable,Not Applicable,Not Applicable,Not Applicable,2.1% received pre-incision antibiotic prophylaxis; only two (0.4%) received it at the correct time (30-60 min before incision),467,225,48.20%,"Clinical examination at follow-up visits, CDC criteria, structured telephone interview and algorithm",106,Coagulase-negative Staphylococcus spp.,Not Applicable,Staphylococcus aureus,MRSA accounted for 79% (34/43) of S. aureus isolates,"Gram-negative bacteria (E. coli, Proteus spp., Coliform, Klebsiella spp., Pseudomonas aeruginosa)",Not Applicable,"High MRSA prevalence (79%) among S. aureus isolates, possibly related to inappropriate use of third-generation cephalosporins",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Average length of stay post-CS for all women was 2 days; majority discharged within 3 days after CS,Not Applicable,Not Applicable,"Inappropriate use of antibiotics (esp. third-generation cephalosporins), lack of antimicrobial stewardship, possible healthcare-associated infections, overcrowding of labour and post-delivery wards",On-the-job training and supervision for junior doctors in theatre recommended; ongoing coordinated interventions of infection prevention and antimicrobial stewardship at DRRH,"High rate of SSI, lack of consistent protocol for antibiotic prophylaxis, need for review of national guidelines and internal protocols, incomplete screening for diabetes, high rate of lost to follow-up",No consistent protocol for antibiotic prophylaxis available; majority of women tested for HIV as per national guidelines; ongoing intervention to revise surgery and antibiotic protocols at DRRH,Not Applicable,Not Applicable,"The incidence of post-caesarean section SSI at DRRH was extremely high (48.2%), with most infections detected within nine days post-surgery and a very high prevalence of MRSA. Urgent interventions are needed for infection prevention and control, antimicrobial stewardship, and improvement of evidence-based surgical and antibiotic protocols.","Study had a high rate of loss to follow-up (29.7%); age statistics not reported; resistance data only for MRSA; no morbidity, mortality, or economic impact data presented."
"Worku Sebele, Tamrat Abebe, Ashenafi Alemu, Berhanu Seyoum, Göte Swedberg, Alemseged Abdissa, Adane Mihret, Getachew Tesfaye Beyene",2023,Bacterial profile of surgical site infection and antimicrobial resistance patterns in Ethiopia: a multicentre prospective cross-sectional study,Ethiopia,Multicentre prospective cross-sectional study,July 2020 - August 2021,"University Teaching Hospitals: Debre Tabor Comprehensive Specialized Hospital, Hawassa University Teaching Hospital, Jimma University Teaching Specialized Hospital, Tikur Anbessa Specialized Hospital",752,Patients of all ages with clinically suspected surgical site infection admitted for elective and emergency surgery,"All patients with suspected SSI admitted for elective and emergency surgery, who developed signs and symptoms of SSI within 30 days post-op (or 90 days for implants), who provided consent/assent","Patients on antibiotics within preceding ten days, SSI later than 30 days after operation, refusal to consent/assent, infected burn wounds",Median age 28 years (range 3 days to 85 years),44.40%,"General surgery, orthopedic surgery, pediatric surgery, obstetrics and gynecology wards",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,752 (study population were SSIs),Not Applicable,"Clinical diagnosis by attending physicians; laboratory confirmation by wound discharge culture and identification (MALDI-TOF, Gram stain, biochemical tests)",494,Staphylococcus aureus,"Penicillin 90.1%, Ampicillin 76.5%, Clindamycin 7.8%, Chloramphenicol 10.6%, Gentamicin 12.4%, Cefoxitin (methicillin resistance) 22.7%, Vancomycin 0%",Escherichia coli,"Ampicillin 94.6%, Ceftriaxone 99%, Cefotaxime 93.8%, Ceftazidime 79.4%, Cefepime 77%, Cefuroxime 73.5%, Ampicillin-sulbactam 72%, TMP-SMX 71.5%, Tetracycline 70.6%, Gentamicin 57.8%, Chloramphenicol 41.2%, Ertapenem 24.5%, Imipenem 11.6%, Amikacin 10.8%, Meropenem 9.8%",Klebsiella pneumoniae,"Ampicillin 100%, Ceftriaxone 100%, Cefotaxime 93.8%, Amoxicillin-clavulanic acid 91.7%, Ceftazidime 88.5%, Cefepime 81.2%, Cefuroxime 77.1%, Tetracycline 66.7%, Ertapenem 43.8%, Meropenem 41.7%, Amikacin 33.3%, Imipenem 29.2%","Carbapenem resistance in Enterobacteriaceae: meropenem 17.6%, imipenem 20.3%, ertapenem 32.9%. E. coli: ertapenem 24.5%, imipenem 11.6%, meropenem 9.8%. Klebsiella pneumoniae: ertapenem 43.8%, meropenem 41.7%, imipenem 29.2%. A. baumannii: ertapenem 92.1%, meropenem 84.2%, imipenem 65.9%. All S. aureus sensitive to vancomycin.",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Broad-spectrum or inappropriate antibiotics use, lack of antimicrobial stewardship, misuse/overuse of antibiotics, un-updated empirical therapy",Standard bacteriological tests and routine antimicrobial susceptibility testing (AST); recommendation for antimicrobial stewardship and empirical therapy guided by local AST,"Scarcity of ongoing surveillance data, reliance on phenotypic lab methods in prior studies, lack of AMR data in previous work; limited ability to investigate anaerobic bacteria or fungi due to lab resource constraints",Hospitals have started establishing bacteriology labs and AST capacity with external support; need for regular national surveillance and monitoring of AMR patterns,Not Applicable,Not Applicable,"E. coli and S. aureus are the leading SSI isolates in Ethiopia. High antimicrobial resistance exists, especially to ceftriaxone and carbapenems. Emergence of diverse and new bacterial etiologies was noted. Effective antimicrobial stewardship and routine AST are critical. National-level surveillance and guideline adherence are needed to curb rising MDR SSI.","Specific procedures performed not detailed in the text. Outcomes regarding morbidity, mortality, hospital burden, and costs not reported. Sample size matches across sections. All AMR data referenced laboratory-based resistance rates."
"Worku Sebele, Tamrat Abebe, Berhanu Seyoum, Ashenafi Alemu, Yidenek Shimelash, Marechign Yimer, Alemseged Abdissa, Getachew Tesfaye Beyene, Göte Swedberg, Adane Mihret",2023,Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus among Patients Diagnosed with Surgical Site Infection at Four Hospitals in Ethiopia,Ethiopia,Multicenter Cross-sectional study,July 2020 - August 2021,"Four university teaching hospitals (Debre Tabor Comprehensive Specialized Hospital, Tikur Anbessa Specialized Hospital, Hawassa University Teaching Hospital, Jimma University Teaching Hospital)",752,"Patients of all ages admitted for elective and emergency surgery in general surgery, gynecology/obstetric, and orthopedics wards who developed SSI within 30 days post-operation","All surgical patients, regardless of age, who underwent surgery during the study period and developed signs and symptoms of SSI within 30 days","Patients who developed SSIs after 30 days following the operation, those who refused to participate, patients with infected burn wounds, and those on treatment",Mean 35 ± 28.3 years; Median 30 years,41.7,"General Surgery, Gynecology/Obstetrics, Orthopedics",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,752,Not Applicable,"Clinical diagnosis, confirmed by wound culture",163 S. aureus isolates; 40 MRSA isolates (cefoxitin resistant); 11 mecA gene-positive Staphylococci,Staphylococcus aureus,"24.5% of S. aureus isolates were MRSA (resistant to penicillins, cephalosporins, and carbapenems, except ceftaroline/ceftobiprole); among MRSA, 12.9% carried mecA gene; 0.6% showed vancomycin resistance",Mammaliicoccus sciuri (formerly Staphylococcus sciuri),Six isolates (15% of cefoxitin-resistant isolates); 83.3% carried mecA gene; all were vancomycin sensitive,Staphylococcus warneri / Staphylococcus haemolyticus / Staphylococcus epidermidis (each n=1),"S. haemolyticus: mecA positive and vancomycin resistant; S. warneri: mecA positive, vancomycin sensitive; S. epidermidis: cefoxitin resistant, mecA and femA negative","MRSA resistant to penicillins, cephalosporins, carbapenems. One S. haemolyticus isolate showed vancomycin resistance (MIC > 8 ug/mL)",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Age ≥ 61 years, prolonged hospital stay (≥7 days), previous antibiotic use, and antimicrobial prophylaxis during operation associated with higher risk of MRSA SSI","Prompt infection prevention and control measures, strict adherence to infection prevention methods, periodic surveillance, and initiation of antimicrobial stewardship programs recommended",Molecular epidemiology of MRSA and VRSA poorly documented in Ethiopia; need for tailored strategies to control MRSA in specific hospitals; further investigation of non-aureus Staphylococci as reservoirs for mecA gene and potential for gene transfer,Hospitals have microbiology laboratories for culture and susceptibility testing; authors highlight need for periodic surveillance and antimicrobial stewardship at hospital level,Not Applicable,Not Applicable,"High prevalence of mecA carriage among CoNS and variable epidemiology of MRSA between hospitals. Older age, longer hospital stays, previous antibiotic use, and certain prophylaxis practices are risk factors. Infection control and stewardship programs are essential.","No direct reporting of SSI incidence rate or total procedures performed. Clinical outcomes such as morbidity, mortality, and hospital burden not reported. Antibiotic resistance patterns for pathogens other than S. aureus are limited to gene carriage. Pathogen 3 field merged due to single isolates. Study focused on molecular epidemiology and risk factors, not direct clinical or economic outcomes."
"Worku Sebele, Tamrat Abebe, Berhanu Seyoum, Bikila Alemu, Gebrie Denkayehu, Tamrayehu Seyoum, Dawit Hailu Alemayehu, Alemseged Abdissa, Getachew Tesfaye Beyene, Adane Mihret, Göte Swedberg",2024,Molecular characterization of carbapenemase and extended spectrum beta-lactamase producing Acinetobacter baumannii isolates causing surgical site infections in Ethiopia,Ethiopia,Multicenter cross-sectional study,July 2020 - August 2021,"Four tertiary referral hospitals (Debre Tabor Comprehensive Specialized Hospital, Hawassa University Comprehensive Specialized Hospital, Jimma University Specialized Hospital, Tikur Anbessa Specialized Hospital)",752 SSI patients enrolled (493 culture positive),Patients of all age groups diagnosed with surgical site infection admitted to four Ethiopian referral hospitals,"All age groups; patients diagnosed with SSI confirmed clinically at the hospital; diagnosis confirmed as SSI (pain, redness, edema, tenderness, gaping, abscess or purulent discharge, fever >38°C) within 30 days of operation for those without implant",Patients who had been on antibiotics within the preceding ten days,Median 30 years (range 5 days - 70 years),48.8% female (21/43 Acinetobacter-positive patients),"General Surgery, Orthopedics, Paediatrics/ICU",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,752 wound cultures performed (one per SSI patient),752 (clinically diagnosed),Not Applicable,"Clinical assessment by surgeon: infection characterized by pain, redness, edema, tenderness, gaping, abscess/purulent discharge, fever >38°C within 30 days of operation for those without implant",493 culture-positive isolates (43 Acinetobacter species),Acinetobacter baumannii,"93% ESBL positive (by CDT); 95.3% resistant to ceftriaxone; 46.5% harbored carbapenemase genes; carbapenem and cephalosporin resistance genes (blaOxA-23, blaOxA-69, blaNDM-1, blaCTX-M-15); high prevalence of multidrug resistance",Acinetobacter pittii,"Both isolates (2) 100% positive for beta-lactamase genes, 100% ESBL and ceftriaxone resistance",Acinetobacter soli,Both isolates (2) negative for beta-lactamase genes; 100% ceftriaxone resistance,85.7% of Acinetobacter isolates carbapenem resistant; detection of blaNDM-1 genes conferring resistance to carbapenems; 95.3% resistant to cephalosporins (ceftriaxone),Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Extensive antibiotic misuse, poor stewardship, co-existence of multiple resistance genes, horizontal gene transfer via plasmids, use of third-generation cephalosporins, and carbapenems",Strict infection prevention and control procedures in health facilities; recommendation for effective antibiotics stewardship,"Small number of Acinetobacter isolates, possibly not representative for the community; scarcity of data on genetic epidemiology of resistant Acinetobacter in East African countries; need for improved detection and surveillance","Reference quality control procedures; lab capacity for MALDI-TOF MS, PCR, and whole-genome sequencing performed at national institutes; recommendation for national antimicrobial policy and infection control",Not Applicable,Not Applicable,"The frequency and co-existence of ESBL and carbapenemase-producing genes in Acinetobacter species, particularly A. baumannii, is extremely alarming and calls for strict infection prevention and control procedures and effective antibiotic stewardship. The emergence of multidrug-resistant Acinetobacter may significantly limit treatment options in Ethiopian hospitals.","Sample size for Acinetobacter isolates is small; no information on specific surgical procedures, economic outcomes, morbidity/mortality rates, or comparator/intervention groups. Most data focused on molecular resistance epidemiology; SSI incidence rate per procedure is not explicitly stated."
"Ali Abdurrahman, Daniel Gebretsadik, Kassu Desta",2023,"Incidence of surgical site infection, bacterial isolate, and their antimicrobial susceptibility pattern among patients who underwent surgery at Dessie Comprehensive Specialized Hospital, Northeast Ethiopia",Ethiopia,Cross-sectional,"July 22 to October 25, 2016",Dessie Comprehensive Specialized Hospital (tertiary referral hospital),338,Patients from obstetrics and gynecology and general surgical wards hospitalized for clean or clean contaminated surgeries,"Patients admitted to obstetrics and gynecology and general surgical wards who underwent clean or clean contaminated surgeries, and/or those willing to give informed consent","Patients with infection occurring 30 days after operation with no implant, infection on episiotomy, contaminated wounds, procedures not incising healthy skin (e.g., opening abscesses), pediatrics below 15 years, orthopedic surgeries",Mean: 35.25 (SD 15.07) years; Median: 28 years,74.30%,"General Surgery, Obstetrics & Gynecology","Appendix surgery (APPY), colon surgery (COLO), cesarean section (CSEC), herniorraphy (HER), abdominal hysterectomy (HYST), prostate surgery (PRST), small bowel surgery (SB), vaginal hysterectomy (VHYS), exploratory laparotomy (XLAP)",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,338,"49 (clinical diagnosis), 41 (culture-confirmed)","14.5% (clinical), 12.13% (culture-confirmed)","Clinical evidence of infection by residents using CDC SSI criteria, wound swab for bacteriological confirmation",48,Staphylococcus aureus,"100% penicillin resistance, 55.6% cotrimoxazole resistance, 55.6% cefoxitin resistance, 38.9% tetracycline resistance, 42.86% methicillin-resistant (MRSA)",Escherichia coli,"66.67% ESBL producers, 91.3% ampicillin resistance, 87% augmentin resistance, 73.9% cotrimoxazole resistance, 78.3% ceftriaxone resistance, 52.2% ciprofloxacin resistance, 47.8% cefepime resistance, 34.8% gentamicin resistance",Klebsiella species,"Two of the K. pneumoniae were ESBL producers, resistance to similar antibiotics as other Enterobacteriaceae (high resistance to ampicillin, augmentin, cotrimoxazole, ceftriaxone; sensitivity to amikacin)",High resistance to ceftriaxone (3rd generation cephalosporin) among Enterobacteriaceae (78%); ESBL producing strains observed for E. coli and K. pneumoniae; low resistance to amikacin,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Antimicrobial drug overuse, overdosing, drug prescription without proper susceptibility test, unethical drug promotion, self-medication, long duration of hospitalization",Periodic surveillance of SSI and antibiograms recommended; physician notification of resistance results for patient management,Study limited to a single institution; lack of data on other hospital wards; inability to isolate anaerobic bacteria due to limited laboratory facilities,In-country data sharing and physician communication of lab results; periodic surveillance recommended; no mention of wider policy or surveillance infrastructure beyond hospital,Not Applicable,Not Applicable,"An average rate of SSI was found to be reported and a significant number of bacterial isolates detected. The rate of MDR was higher, particularly among Gram-negative isolates. Periodic surveillance of SSI incidence and bacterial profiles, along with antibiotic susceptibility testing, should be performed.","Clinical SSI cases (49) exceed culture-confirmed (41); some data (hospital stay, costs, mortality) not reported; ESBL data available only for E. coli and Klebsiella spp."
"Akoachere Jane-Francis Tatah Kihla, Palle John Ngunde, Mbianda Soupsop Evelyn, Nkwelang Gerard, Roland Ndip Ndip",2014,"Risk factors for wound infection in health care facilities in Buea, Cameroon: aerobic bacterial pathogens and antibiogram of isolates",Cameroon,Cross-sectional observational study,October 2010 - March 2011,"Mount Mary Health Center (private) and Regional Hospital Annex (public), Buea, Cameroon",212,"Hospitalized patients of all ages with clinically diagnosed infected wounds (including burns, ulcers, open wounds, and post-operative wounds)",Patients hospitalized and clinically diagnosed with wound infection; consent to participate; wounds with purulent discharge or signs of inflammation,Patients without clinical diagnosis of infected wound; patients who did not give consent,Range 7 months to 80 years; Age group breakdowns provided but no mean/median or SD/IQR,42%,"General Surgery (includes post-operative wounds, burns, ulcers, open wounds)","Not specified (includes surgical wounds, burn wound care, ulcer and open wound management)",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,169,79.70%,"Clinical diagnosis based on purulent discharge or signs of inflammation (erythema, pain, tenderness, warmth or induration); aerobic bacterial culture",169,Staphylococcus aureus,"Resistant to oxacillin (100%), chloramphenicol (95.8%), erythromycin (97.9%), co-trimoxazole (100%), doxycycline (79.2%), ampicillin (95.8%), ceftazidime (52.1%). Exhibited multidrug resistance (CAZR SXTR DXTR CR ER AMPR).",Pseudomonas aeruginosa,"Resistant to oxacillin (100%), co-trimoxazole (100%), doxycycline (84.6%), ampicillin (92.3%), augmentin (23.1%), ceftazidime (12.8%). Exhibited multidrug resistance (SXTR DXTR CR AMPR ATMR).",Klebsiella pneumoniae,"Resistant to oxacillin (100%), co-trimoxazole (100%), chloramphenicol (95.5%), erythromycin (95.5%), ampicillin (95.5%), aztreonam (95.5%). Exhibited multidrug resistance (SXTR DXTR CR AMPR ATMR).","High resistance to third-generation cephalosporins (ceftazidime, ceftriaxone) and aminoglycosides observed in some isolates; all isolates resistant to oxacillin (indicative of MRSA)",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Widespread empiric use of broad-spectrum antibiotics; antibiotics sold without prescriptions by unauthorized persons; high misuse of antibiotics; lack of adherence to aseptic practices; shortage of qualified personnel; poor sterilization practices; lack of clean water in hospitals,Recommendations for regular surveillance of pathogens and their susceptibility patterns; strengthening infection control and drug dispensing policies; collaboration between microbiologists and clinicians; use of antimicrobial agents or drug combinations with wider spectra for prophylaxis or treatment; constant supply of potable water; consideration of natural products or non-antimicrobial methods for treatment,Did not evaluate anaerobic/fungal pathogens; did not determine minimum inhibitory concentrations; lack of comprehensive local data on wound infection and antibiotic susceptibility; urgent need for qualified nursing staff; gaps in infection control and surveillance,Hospital management boards and regional health authority had oversight; need for stronger infection control and drug dispensing policies identified; laboratory facilities for aerobic culture available but no mention of surveillance/reporting systems,Not Applicable,Not Applicable,Wound infections in healthcare settings are highly prevalent and frequently caused by multidrug resistant bacteria; infection control strategies and rational antibiotic use are urgently needed; regular surveillance and constant supply of clean water could reduce infection risk; collaboration between clinicians and microbiologists is essential to improve outcomes.,"Dates in abstract (October 2010 - March 2011) and results section (October 2009 - March 2010) differ; mean/median age, total procedures, and economic data not available; study focused on aerobic pathogens only; monomicrobial infections only identified."
"Kachipedzu Amos Tumizani, David King Kulapani, Samuel James Meja, Janelisa Musaya",2024,"Surgical site infection and antimicrobial use following caesarean section at QECH in Blantyre, Malawi: a prospective cohort study",Malawi,Prospective cohort,February 2023 - July 2023,"Queen Elizabeth Central Hospital (QECH), tertiary referral hospital",208,Pregnant women undergoing caesarean section,All women who underwent caesarean section procedure at QECH between 1st February 2023 and 31st July 2023,Women who underwent caesarean section in other health facilities,Mean 26.1 (SD 6.2) years; Range 15-42 years,100% female,Obstetrics & Gynecology,Caesarean section,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,208,20,9.61%,30-day clinical follow-up and microbiological wound culture using CDC criteria,5 (culture positive out of 10 tested specimens from 20 SSI cases),Staphylococcus aureus,"Resistant to clindamycin, erythromycin, gentamicin, and cefoxitin",Enterobacteriaceae,"Resistant to chloramphenicol and trimethoprim-sulfamethoxazole; sensitive to ciprofloxacin, meropenem, amikacin, and tigecycline; intermediate to gentamicin",Acinetobacter baumannii,"Resistant to ceftriaxone, ciprofloxacin, cefotaxime, and tigecycline; sensitive to gentamicin",Staphylococcus aureus resistant to cefoxitin (MRSA marker); Acinetobacter baumannii resistant to ceftriaxone and ciprofloxacin; Enterobacteriaceae sensitive to meropenem (not resistant),Not Applicable,Not Applicable,60%,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Inappropriate antimicrobial use (prolonged prophylaxis after surgery without microbiological confirmation), empiric use of broad-spectrum antibiotics, lack of routine culture before prescribing antibiotics","Recommendations for intensive infection prevention and control practices, establishment of antimicrobial stewardship (AMS) programs, and routine surveillance of SSIs at QECH","Limited microbiological data due to loss to follow-up, small sample size of isolates, restriction to CS cases only, need for further research on antimicrobial resistance patterns and drivers, lack of exploration of best approaches to address AMR",Need for AMS programs and routine surveillance highlighted; limited current laboratory data due to missed follow-up/culture,Not Applicable,Not Applicable,"Incidence of 9.61% SSI following CS at QECH is higher than in some other developing countries. Most patients received post-CS antibiotics without microbiological confirmation, promoting potential antimicrobial resistance. There is an urgent need for intensive infection control, AMS program establishment, and routine SSI surveillance.","Number of SSI cases determined both clinically (10) and by culture (10); only 5 cultures positive. No data on mortality, re-operation, length of stay, or economic burden. No explicit risk of bias tool mentioned. The study is limited to one hospital and to CS cases only."
"Kefale Belayneh, Gobezie T Tegegne, Amsalu Degu, Mulugeta Molla, Yitayih Kefale",2020,Surgical Site Infections and Prophylaxis Antibiotic Use in the Surgical Ward of Public Hospital in Western Ethiopia: A Hospital-Based Retrospective Cross-Sectional Study,Ethiopia,Retrospective Cross-sectional,1st June 2019 to 31st May 2020,"Finote Selam General Hospital, Northwest Ethiopia",281,Patients admitted for elective or emergency surgical procedures,Medical records of surgical patients admitted from 1st June 2019 to 31st May 2020 for elective or emergency surgical procedures with complete medical records,"Medical records that did not have complete information, such as list of surgical antibiotics prophylaxis",Not Applicable,44.80%,"General Surgery, Gastrointestinal Surgery, Gynecologic Surgery, Urological Surgery, Orthopedic Surgery, Other (neck surgery and appendectomy)","General surgery, gastrointestinal surgery, gynecologic surgery, urological surgery, orthopedic surgery, neck surgery, appendectomy",Not Applicable,Not Applicable,Not Applicable,Not Applicable,92.8% appropriate choice of antibiotics; 94.4% appropriate dosage; 88.6% received SAP; 7.2% of prescribed antibiotics were inappropriate,281,55 (19.6% of 281),19.60%,Medical record review following WHO guideline operational definitions,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"High rates of inappropriate prophylactic antibiotic use, poor infection control practices, and extended duration of hospital stay; general risks identified include inappropriate choice, timing, and SAP duration",Assessing appropriateness based on standard treatment guidelines and recommending adherence to established SAP protocols,Lack of adequate infection control systems; poor practices; inappropriate use of antibiotics; lack of data about SSIs in Northwest Ethiopia,"Data collection based on WHO guidelines, Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery; general mention of adherence but no specific policy or surveillance infrastructure description",Not Applicable,Not Applicable,"The prevalence of SSI was relatively high despite most surgical patients being given prophylactic antibiotics. Presence of comorbidity, contaminated and dirty wound classes, lack of prophylactic antibiotics, inappropriate timing and prolonged duration of surgical antibiotic prophylaxis were significantly associated with development of SSIs. Healthcare professionals should adhere to recommended guidelines for prescribing appropriate prophylactic antibiotics.","No microbiological data or pathogen/resistance information presented; SSI identification based on retrospective review and clinical/institutional definitions; economic, morbidity, and mortality outcomes not addressed."
"Billoro, Mengistu Nunemo, Seid E. Gelan",2019,"Evaluation of antimicrobial prophylaxis use and rate of surgical site infection in surgical ward of Wachemo University Nigist Eleni Mohammed Memorial Hospital, Southern Ethiopia: prospective cohort study",Ethiopia,Prospective cohort study,"January 1 - September 1, 2017","Wachemo University Nigist Eleni Mohamed Memorial Hospital (WUNEMMH), government hospital, surgical ward",255,Patients admitted for elective and emergency surgical procedures who fulfilled eligibility criteria,All patients admitted for elective and emergency surgical procedures who fulfilled eligibility criteria during the study period,"Patients not willing to participate, those receiving antimicrobial during admission or stopped receiving within 48 hours before operation, and patients with initial diagnosis suggestive of infection",Not Applicable,42.35%,"General Surgery, Obstetrics & Gynecology, Head and Neck, Genitourinary, Breast, Hepato-biliary","Caesarean section, appendectomy, head and neck surgery, genitourinary surgery, hernia repair, breast surgery, hepato-biliary surgery, lipoma excision",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,255,42,16.50%,"Diagnosis by WUNEMMH surgeons, wound classification according to CDC criteria, wound specimens collected and cultured for confirmation","Not explicitly stated, but percentages for 4 species given: n (not specified), Klebsiella pneumoniae (60%), Staphylococcus aureus (17.8%), Escherichia coli (11.1%), Pseudomonas aeruginosa (11.1%)",Klebsiella pneumoniae,"Resistant to ampicillin, tetracycline, erythromycin; 88.9% susceptible to ciprofloxacin and ceftriaxone",Staphylococcus aureus,"Sensitive to ciprofloxacin, cloxacillin, ceftriaxone, gentamycin; resistant to erythromycin, chloramphenicol, and ampicillin; 100% sensitive to ceftriaxone and gentamycin",Escherichia coli,100% resistant to ciprofloxacin and ceftriaxone,"Klebsiella pneumoniae had high susceptibility to ciprofloxacin and ceftriaxone; study notes some resistance to ceftriaxone observed in Kenya, but in this cohort no critical resistance described; chloramphenicol resistance frequent","Not Applicable (background mentions 6.5-11 days extra in other settings, but not specific to this cohort)",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Unnecessary and prolonged administration of antibiotics; inappropriate prophylactic antimicrobial use; limited surveillance and testing capacity,Surveillance of SSI rates and feedback to surgeons/hospital authorities recommended; rational antibiotic use policy suggested,"Professionals' related variables, antiseptics used, surgical equipment sterilization methods, and anesthesia type not included due to resource constraints; lack of periodic surveillance on causative agents and antibiotic sensitivity",Recommendation for periodic surveillance systems and feedback mechanisms; discussion of local antibiogram need; current surveillance is limited,Not Applicable,Not Applicable,"The rate of SSI was relatively high (16.5%). Klebsiella pneumoniae was the most common causative agent. SSI rates are associated with prolonged surgery waiting time, longer operation, early administration of antibiotics, and smoking. The causative organisms were generally sensitive to ceftriaxone and ciprofloxacin. Periodic surveillance and locally adapted antibiotic policies are needed.","Total SSI isolate count not precisely stated; antibiotic resistance for E. coli seems extremely high but the denominator is unclear; some background hospital stay/cost figures are provided from other countries, not this cohort."
"Nitrushwa David, Rahel Ghebre, Marie A Unyuzimana, Urania Magriples, Maria Small, Stephen Rulisa",2021,Single vs. extended antibiotic for prevention of surgical infection in emergent cesarean delivery,Rwanda,Randomized Controlled Trial,1st July 2015 to June 2016,"Ruhengeri Hospital, a large rural hospital",301,Women undergoing emergency cesarean section,All women admitted in maternity at Ruhengeri Hospital during the study period and had agreed to be enrolled after written informed consent,"Women with signs of ongoing infections (chorioamnionitis, fever during labor, premature rupture of membranes for more than 18 hours), failed instrumental delivery at complete dilatation, or not receiving timely antibiotics",Not Applicable,100,Obstetrics & Gynecology,Emergency cesarean section,147,Single dose 2 g Ampicillin 15 to 60 minutes before skin incision,154,2 g Ampicillin prior to skin incision plus 1 g every 8 hours for 72 hours (multiple doses),Not Applicable,301,12,4.00%,"Defined as fever, tenderness and swelling of the wound or loss of continuity with pus discharge; assessed at discharge and by phone interview up to day 30",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Misuse and overuse of antibiotics, prolonged antimicrobial prophylaxis, broad spectrum antibiotics, lack of standardized protocols","Rigorous protocols for antibiotic prophylaxis (timing before incision), regular operating room sterilization, patient education about infection signs and surveillance through phone follow-up","Unexpected low SSI incidence, limited evidence on prophylaxis duration in low-resource settings, insufficient sensitivity of phone follow-up for diagnosis of non-SSI infections, inability to report on secondary outcomes such as endometritis",Limited data on SSI rates in Rwanda; suggestion of lack of evidence-based standardized protocols in low-resource maternity settings,Not Applicable,Not Applicable,"Compliance to infection control measures can reduce the rate of SSIs. There was no significant difference between the use of a single vs multiple doses of prophylactic antibiotics in our study, but the SSI rate was low.","No data reported on microbiology, resistance patterns, or economic endpoints; all SSIs were clinically diagnosed without wound cultures. Study was limited by provider participation, low SSI rate, and may have missed non-SSI infections due to methodological constraints."
"Derick Hope DD, Lucas Ampaire, Caesar Oyet, Enoch Muwanguzi, Hillary Twizerimana, Richard Onyuthi Apecu",2019,"Antimicrobial resistance in pathogenic aerobic bacteria causing surgical site infections in Mbarara regional referral hospital, Southwestern Uganda",Uganda,Descriptive cross-sectional,"June to August, 2015","Mbarara Regional Referral Hospital (MRRH), surgical, obstetrics/post-natal, gynecology, and orthopedics wards",83,Postoperative patients in study wards with clinical surgical site infection (SSI) within 30 days of operation,"Consented postoperative patients in surgical, obstetrics/post-natal, gynecology, and orthopedics wards presenting with clinical SSI within 30 days of operation",Not Applicable,Mean 26.51 ± 13.56 years (range 6-75 years),65.06%,"General Surgery, Obstetrics & Gynecology, Orthopedics","Caesarian section (C-section), surgical debridement, laparotomy, open reduction and internal fixation (ORIF), others",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,83,83,Not Applicable,Guidelines on prevention of SSI by CDC and protocol by European Centre for Disease Prevention and Control (ECDC); clinical diagnosis with bacteriological confirmation using wound swabs and standard microbiological techniques,93,Klebsiella species,"Ampicillin (100%), ceftriaxone (85.19%), sulfamethoxazole/trimethoprim (81.48%), gentamicin (81.48%), ciprofloxacin (55.56%); 100% MDR, 25.93% resistant to all antibiotics tested",Staphylococcus aureus,"Ampicillin (100%), oxacillin (100%), gentamicin (75%), ceftriaxone (90%), erythromycin (85%), sulfamethoxazole/trimethoprim (75%), ciprofloxacin (50%); 45% resistant to all antibiotics tested",Proteus species,"Ampicillin (100%), sulfamethoxazole/trimethoprim (90.91%), ceftriaxone (81.82%), gentamicin (81.82%), ciprofloxacin (63.64%); 18.18% resistant to one antibiotic, 36.36% resistant to five antibiotics",High resistance to ceftriaxone (3rd generation cephalosporin): Gram negative: 88.89%; Klebsiella: 85.19%; E. coli and Enterobacter spp: 100%,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Injudicious/irrational use of antibiotics (especially ampicillin); self-treatment with over-the-counter antibiotics; antibiotic misuse without evidence of causative agent and antibiogram; selection pressure in hospital environment,Recommendations for preoperative rectal swabs to detect colonization with MDR bacteria; periodic surveillance of SSI including aetiology and susceptibility profiling; strict adherence to infection control; guided therapy by susceptibility patterns,"Absence of data on anaerobic bacteria and fungi due to financial constraints; limited surveillance and notification systems; limited data on burden, aetiology, and susceptibility patterns of SSI in setting","Reference to lack of standardized diagnosis, absence of surveillance and notification systems in developing countries; Study recommends periodic SSI surveillance and laboratory-guided therapy",Not Applicable,Not Applicable,"SSI remains a major problem for postoperative patients; there is an alarming MDR rate of 86% among bacterial isolates and high resistance to commonly used antibiotics. Antibiotic therapy should be guided by susceptibility patterns. Periodic surveillance, infection control, and judicious antibiotic use are urged.","Incidence rate of SSI not reported for hospital admissions overall, only for those with clinical SSI; outcomes such as hospital stay, mortality, economic costs not provided. No explicit reporting of a risk of bias assessment."
"Odoko Desta, Abera Kumalo, Getachew Alemu, Tigistu Demisse, Teshale Mulugeta, Muluneh Temesgen",2024,Extended-spectrum ß-lactamase and carbapenemase producing Enterobacteriaceae among patients suspected with surgical site infection at Hospitals in Southern Ethiopia,Ethiopia,Hospital-based cross-sectional study,"June 1, 2022 - August 30, 2022","Two hospitals: Wolaita Sodo Comprehensive Specialized Hospital and Sodo Christian General Hospital, Sodo Town, Southern Ethiopia",422,Patients of all ages clinically suspected of having surgical site infection and admitted to two hospitals in Southern Ethiopia,"Patients clinically suspected of having surgical site infection (deep incisional, organ/space, and superficial incisional SSI as per CDC guidelines) during the study period",Not Applicable,"Median age group was 31-44 years (53.1% of sample), age range 5-96 years; SD/IQR Not Applicable",55.70%,"Orthopedics, General Surgery, Obstetrics & Gynecology",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"422 suspected, 100 culture-positive Enterobacterales infections (SSI definition per CDC criteria)",23.7% (100/422 patients with confirmed Enterobacterales infection),Clinical criteria per CDC guidelines; laboratory confirmation by culture of wound swabs/aspirates,"100 Enterobacterales isolates (69 Enterobacteriaceae, remainder Morganellaceae)",Escherichia coli,"Cefepime (90%), Ceftriaxone (93.2%), Ceftazidime (90%), Amoxicillin-clavulanic acid (96.6%), Ciprofloxacin (75.9%), Gentamicin (44.8%)",Klebsiella pneumoniae,"Cefepime (100%), Ceftriaxone (100%), Ceftazidime (100%), Amoxicillin-clavulanic acid (100%), Gentamicin (85.7%), Ciprofloxacin (78.6%), Meropenem (64.3%)",Klebsiella oxytoca,"Cefepime (87.5%), Ceftriaxone (87.5%), Ceftazidime (87.5%), Amoxicillin-clavulanic acid (100%), Gentamicin (87.5%), Ciprofloxacin (62.5%), Meropenem (25%)",Carbapenem (meropenem) resistance 27.9% overall among Enterobacteriaceae; carbapenemase-producing Enterobacteriaceae accounted for 15% of isolates; high resistance (>90%) to 3rd and 4th generation cephalosporins,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Patients with SSI due to ESBL/CPE had a higher length of stay; statistically significant association with SSI identified for hospital stay >8 days (AOR = 3.81, 95% CI 2.08-6.95), actual median/mean or days not specified",Not Applicable,Not Applicable,"Prolonged hospital stay, overuse of antibiotics, self-medication, prescribing antibiotics without susceptibility testing, absence of stewardship programs",Culture-based diagnosis and antimicrobial susceptibility testing (AST) for SSIs; recommendation for antibiotic selection based on culture and sensitivity results,"Lack of molecular testing for resistance mechanisms, resource constraints, limited generalizability from only two hospitals, lack of AMR surveillance and stewardship programs in Southern Ethiopia",AMR surveillance and stewardship described as lacking in study hospitals and region; no formal policies or infrastructure referenced,Not Applicable,Not Applicable,"High rates of ESBL and carbapenemase-producing Enterobacteriaceae are present in surgical site infections in Southern Ethiopia; prolonged hospital stay significantly increases risk; high levels of multidrug resistance and resistance to key antibiotics, particularly 3rd/4th generation cephalosporins; meropenem remains relatively effective but resistance is emerging; empirical therapy should be guided by culture and susceptibility testing; more research and stewardship interventions are urgently needed.","No data reported for surgical procedure types, re-operation, readmission, mortality, cost, or formal risk of bias assessment; microbiological and clinical data robust but some epidemiological rates (e.g., SSIs per procedure) not provided; multi-hospital design but regionally limited."
"Dinda Victor, Gunturu Revathi, Kariuki Sam, Hakeem Abdi, Raja Asad, Kimang'a Andrew",2013,"Pattern of Pathogens and their Sensitivity Isolated from Surgical Site Infections at the Aga Khan University Hospital, Nairobi, Kenya",Kenya,Prospective Cohort,March 2008 - May 2009,"Tertiary referral hospital (Aga Khan University Hospital, Nairobi)",268,Adult patients referred for general surgical procedures (excluding neurological and cardiothoracic surgeries),"Adult patients referred for surgery to Aga Khan University Hospital, Nairobi between March 2008 and May 2009 who had not undergone any surgical procedure in the previous one month","Patients referred for surgery out of disease complications being managed, those on multiple antimicrobial exposures due to chronic care prior to surgery, and all diagnostic surgical procedures",Mean age 38 years; Median age 37 years; (SD/IQR not specified),70.5% (189/268),General Surgery,General surgical procedures (excluding neurological and cardiothoracic surgeries); further detail not provided,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,268,39,7.0% (True SSI rate in clean and clean contaminated wounds); 14.6% overall infection rate post-surgery,Diagnosis by surgeon according to CDC definition; clinical assessment and laboratory confirmation (culture of pus swabs),29 (culture positive cases from SSIs),Staphylococcus aureus,"Ampicillin 60%, Doxycycline 40%, Azithromycin 30%, Augmentin 10%, Cefuroxime 10%, Ciprofloxacin 50%, Chloramphenicol 20%, Oxacillin 10%, Netilmicin 0%, Vancomycin 0%",Coagulase negative Staphylococcus,"Ampicillin 80%, Doxycycline 60%, Azithromycin 60%, Augmentin 40%, Cefuroxime 60%, Ciprofloxacin 20%, Chloramphenicol 40%, Oxacillin 0%, Netilmicin 0%, Vancomycin 0%","Klebsiella spp., E. coli, and Kluyvera spp. (each found in 12.8% of cases; grouped/third most common)","Klebsiella spp.: Cotrimoxazole 67%, Doxycycline 33%, Augmentin 67%, Cefotaxime 67%, Chloramphenicol 33%, Ciprofloxacin 0%, Gentamicin 67%, Cefuroxime 0%","Low MRSA prevalence (only 1 MRSA isolate); All Staphylococci susceptible to Vancomycin; Gram negatives show resistance to cefotaxime, cefuroxime, ciprofloxacin, and gentamicin; Imipenem resistance in P. aeruginosa (50%)",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Prolonged preoperative hospital stay, dirty wounds, prior antibiotic exposure (patients on multiple antimicrobial exposures prior to surgery excluded from study)","Antibiotic prophylaxis given according to institutional policy; Standard operating procedures for sample collection, transport, culture and susceptibility; Surveillance protocols described","Paucity of published reports on hospital pathogens and SSI risk factors in Kenyan hospitals; Lack of anaerobic culture system; SSI not stratified by depth (superficial, deep, organ space)","Laboratory is internationally accredited (ISO 15189:2007), participates in UKNEQAS; Institutional ethical approval obtained; Use of CDC definition for SSI",Not Applicable,Not Applicable,The SSI incidence rate (7.0%) observed in this study was relatively lower than documented in other Kenyan studies. Staphylococcus aureus is the most prevalent pathogen. Prolonged hospital stay and dirty wounds are the risk factors associated with postsurgical sepsis at the hospital.,"SSI case definition used CDC criteria, but SSIs were not stratified by depth. Sample size followed up through 1 month was 262 (6 lost to follow-up). Pathogen 3 includes several species with equal isolation frequency. Specific details of general surgical procedures are not specified."
"Gentilotti Elisa, Pasquale De Nardo, Boniface Nguhuni, Alessandro Piscini, Caroline Damian, Francesco Vairo, Zainab Chaula, Paola Mencarini, Peter Torokaa, Alimuddin Zumla, Emanuele Nicastri, Giuseppe Ippolito",2020,Implementing a combined infection prevention and control with antimicrobial stewardship joint program to prevent caesarean section surgical site infections and antimicrobial resistance: a Tanzanian tertiary hospital experience,Tanzania,Before-after intervention cohort study,"August 2013 - April 2015 (PRE-Int survey: 3 months from August 19, 2013; POST-Int survey: 3 months starting April 1, 2015; overall intervention period between surveys spans 2 years)",Dodoma Regional Referral Hospital (Tanzanian tertiary hospital); Obstetrics & Gynaecology Department,"1377 (664 pre-intervention, 713 post-intervention)",Women undergoing caesarean section,All consecutive women undergoing caesarean section at DRRH during designated 3-month PRE-Int and POST-Int survey periods,Not Applicable,"Not Available (only age categories reported: <20, 21-34, >34 years)",100%,Obstetrics & Gynaecology,Caesarean section,573 (follow-up available in POST-Int survey group),"Combined infection prevention and control measures with antimicrobial stewardship joint program, including formal and on-job training, evidence-based education on AMR, implementation of IPC protocols, AMS multidisciplinary team, pre-incision antibiotic prophylaxis (ampicillin 1g 30-60 min before incision), improvement of operating theatre discipline, optimized antibiotic prescription, standardized skin disinfection, absorbable continuous intradermic sutures",467 (follow-up available in PRE-Int survey group),"Usual care prior to intervention, consisting mainly of post-operative antibiotic courses (typically 8-10 days), variable timing of antibiotic administration, lower rates of prophylactic antibiotic use, less standardized skin disinfection and suture practice",Pre-incision antibiotic prophylaxis administered in 98% of patients post-intervention vs 2% pre-intervention; appropriate timing of prophylaxis achieved in 28% post-intervention,"1040 (patients with follow-up available: 467 pre-, 573 post-intervention)","320 (225 pre-intervention, 95 post-intervention)","48.2% pre-intervention, 16.6% post-intervention","CDC criteria, clinical wound examination by infectious diseases specialist, structured telephone interview; wound swab for culture in suspected cases","168 bacterial pathogens isolated from SSI wounds (106 pre-intervention, 62 post-intervention)",Staphylococcus aureus,"MRSA prevalence: 79% of S. aureus pre-intervention, 21.4% post-intervention; all post-intervention MRSA isolates showed inducible resistance to clindamycin; susceptibility: 43.2% to tetracycline, 13.5% to chloramphenicol, 5.4% to cotrimoxazole (post-intervention)",Coagulase-negative Staphylococcus species,Not Applicable,Klebsiella spp.,"Pre-intervention: 100% Klebsiella spp. isolates were MDROs; post-intervention: 42.8% MDROs (resistant to amoxicillin/clavulanate, ceftriaxone, gentamicin and/or ciprofloxacin)",No resistance to vancomycin and meropenem observed in POST-Int group; high rates of MDR gram-negative organisms (over half of all isolates); 80% of Enterococcus spp. resistant to ampicillin; no detailed rates for 3rd gen cephalosporins/carbapenems beyond above,Not Applicable (mean days of hospitalization for all groups was approximately 2 days),Not Applicable,Not Applicable,Not Applicable,"Not Applicable (2 deaths before discharge reported in pre-intervention group, but not attributed directly to SSI)",Not Applicable,Approximately 2 days (mean) reported for both groups; not stratified by SSI,Estimated hospital cost savings of €1500 during post-intervention (by switching from 3 days IV antibiotics post-op to single-dose pre-op prophylaxis),Estimated personal saving of €3 per patient due to reduction in post-discharge antibiotic prescriptions,"Widespread use of post-operative antibiotics, lack of local AMR surveillance systems, inappropriate antibiotic prescribing practice, supply chain limitations for antibiotics and laboratory disposables","Hospital-based multidisciplinary IPC-AMS program, literature-based education, scheduled seminars, on-job training, prioritized prevention measures, strengthened supply chain for antibiotics/disinfectants/disposables, established AMS team and improved laboratory capability (WHO SLIPTA 3-star accreditation)","Need for efficient national AMR surveillance system, data on MDROs prevalence in Tanzania lacking, study design limitations (not able to isolate effect of individual intervention components or analyze impact of comorbidities such as diabetes or hypertension); require further robust studies","DRRH laboratory improved and achieved WHO AFRO SLIPTA 'three star' recognition; study supported by hospital management and Tanzanian National Institute for Medical Research; however, broader national/regional surveillance still limited",Not Applicable,Not Applicable,"A combined infection prevention and control with antimicrobial stewardship program led to a substantial reduction in caesarean section SSI rates (more than 65% reduction) and MRSA prevalence at a Tanzanian tertiary hospital. Improved IPC and AMS education for hospital staff is essential, and improved SSI/AMR surveillance is warranted. The multidisciplinary approach is effective, but robust multicenter studies are needed to further inform best practice.","Some values (e.g., age Mean/SD, re-operation rate, readmission rate, mortality directly attributable to SSI) not reported; total sample size differs depending on analytic denominator (all enrolled vs. patients with follow-up); pathogen resistance percentages sometimes calculated from subgroup n rather than all isolates."
"Garoy Eyob Yohannes, Yacob Berhane Gebreab, Oliver Okoth Achila, Nobiel Tecklebrhan, Hermon Michael Tsegai, Alex Zecarias Hailu, Abrehet Marikos Buthuamlak, Tewelde Ghide Asfaga, Mohammed Elfatih Hamida",2021,"Magnitude of Multidrug Resistance among Bacterial Isolates from Surgical Site Infections in Two National Referral Hospitals in Asmara, Eritrea",Eritrea,Survey (cross-sectional laboratory-based study),February 2017 - May 2017,"Two national referral hospitals (Halibet National Referral Hospital and Orotta National Referral Hospital), Asmara, Eritrea",83,Male and female patients admitted to surgical wards who developed surgical site infections after surgery; includes pediatric patients,Patients admitted in surgical wards after surgery who developed infection after 48 hours of admission; pediatric patients meeting predefined criteria (with parental consent),Not Applicable,42.65 (SD 13.14) years (range: 2 - 82 years),30.10%,"General Surgery, Orthopedics","Amputations, surgical debridement, fixations (open reduction and internal fixation, removal of internal fixation devices), colonoscopies, appendectomies",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,83,Not Applicable,Clinical diagnosis (infection after 48 hours of admission); confirmation by wound swabs processed by Levine technique and standard microbiological procedures,116,Staphylococcus aureus,"100% resistant to penicillin, 70% oxacillin (MRSA), 60% vancomycin, 25% clindamycin, 25% erythromycin",CONS (Coagulase-negative staphylococci),Not Applicable (resistance profiles not evaluated for CONS),Citrobacter spp.,"100% resistant to ampicillin, 93% cefalexin, 93% ceftazidime, 93% ceftriaxone, 80% nitrofurantoin, 73% tetracycline; other antibiotics also show high resistance","High resistance to third-generation cephalosporins (ceftazidime, ceftriaxone) among Gram-negative bacteria (Citrobacter spp., Escherichia coli, Klebsiella spp., Pseudomonas aeruginosa, Acinetobacter spp.); 60% vancomycin resistance in S. aureus",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Imprudent antibiotic use, poor adherence to infection-control practices, extensive institutional use of cephalosporins for prophylaxis, lack of antimicrobial stewardship, lack of laboratory-based surveillance","Recommendations for stricter infection control policies and guidelines (decontamination, antimicrobial surveillance, antibiotic stewardship, cohorting and decolonization, improved diagnostic services)","Lack of laboratory-based surveillance and reporting, lack of molecular characterization of MDR isolates, absence of infection-control professionals, no adequate compliance studies for infection control, limitations in detecting vancomycin resistance, failure to study sensitivity to some critical drugs (linezolid, carbapenems, piperacillin/tazobactam), lack of country-specific SSI data",No infrastructure for trained infection-control professionals; no laboratory-based surveillance and reporting system; existing practices are rudimentary; need for centralized body for monitoring and reporting; reference laboratory procedures not routinely available,Not Applicable,Not Applicable,"This study found high rates of multidrug-resistant organisms, including HA-MRSA and VRSA, among SSI cases in two referral hospitals in Eritrea. The authors highlight urgent need for better infection control practices, guidelines, and surveillance systems to curb the spread of MDR bacteria and improve outcomes.","Sample size appears consistent throughout text. No data on outcomes such as hospital stay, re-operation, or mortality. Study assessed resistance to a wide range of antibiotics, but linezolid and carbapenems were not evaluated. Risk of bias was not formally assessed."
"Gemedo Misha, Legese Chelkeba, Tsegaye Melaku",2021,Bacterial profile and antimicrobial susceptibility patterns of isolates among patients diagnosed with surgical site infection at a tertiary teaching hospital in Ethiopia: a prospective cohort study,Ethiopia,Prospective cohort study,"April 20 to August 20, 2019",Tertiary teaching and referral hospital (Jimma Medical Center),251,"Adult patients (age ≥18 years) who underwent elective or emergency surgical procedures at general surgery, gynecology/obstetric, and orthopedics wards",Adult patients (age ≥18 years) who underwent either elective or emergency surgical procedures at JMC; followed for 30 days post-op for SSI occurrence,"Patients initially diagnosed with SSIs, died within 48 hours, or refused to participate",Mean 38 (SD 16.3) years,50.20%,"General Surgery, Orthopedics, Gynecology and Obstetrics",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,251,53,21.10%,Clinical assessment by attending physician using CDC SSI surveillance methods and criteria,38,Escherichia coli,"Cefepime 100%, ceftriaxone 55%, cefuroxime 55%, cotrimoxazole 22%, ciprofloxacin 55%, ampicillin 44%. Meropenem 0% resistance (100% effective)",Pseudomonas aeruginosa,"Cefepime 100%, ceftriaxone 100%, meropenem 62.5%, ceftazidime 62.5%, ciprofloxacin 50%, gentamicin 50%",Proteus species,"Cefepime 100%, cefuroxime 100%, ceftriaxone 100%, ciprofloxacin 67%, ampicillin 67%, cotrimoxazole 67%, chloramphenicol 67%","High resistance reported to ceftriaxone (78.79%), cefepime (87.88%); meropenem resistance seen only in Pseudomonas (62.5%), but E. coli 0% resistance to meropenem",SSI doubles the duration of hospital stay (no specific number of days),Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Extra costs due to SSI of between 800 and £ 7000 have been recorded (citation from literature, not new data)",Not Applicable,"Indiscriminate use of antibiotics, especially ceftriaxone as prophylaxis, and empirical prescribing",Strengthening antimicrobial stewardship programs and periodic antimicrobial resistance surveillance recommended; emphasis on routine microbial analysis of samples and antibiogram,"Lack of multi-center studies, limitations in laboratory capacity (no anaerobic cultures), need for antimicrobial resistance surveillance and antibiotic stewardship",Hospital protocol for management of SSI; limitations in microbiology laboratory capacity noted (no anaerobic culture),Not Applicable,Not Applicable,"Gram-negative bacteria, particularly Escherichia coli, were the most common isolates from surgical sites; high rates of antibiotic resistance were observed, highlighting the necessity for routine microbial analysis and stewardship interventions; multi-center and surveillance studies are needed.","Anaerobic bacteria not analyzed due to laboratory limitations. No procedure-specific data, morbidity or mortality outcomes reported. Economic figures quoted from prior studies, not this cohort. No formal risk of bias tool used or described."
"Habtemariam Alekaw Habteweld, Mohammed Yimam, Abate Wondesen Tsige, Yehualashet Teshome Wondmkun, Bedilu Linger Endalifer, Kassahun Dires Ayenew",2023,"Surgical site infection and antimicrobial prophylaxis prescribing profile, and its determinants among hospitalized patients in Northeast Ethiopia: a hospital based cross-sectional study",Ethiopia,Prospective cross-sectional study,"October 1st, 2022 to January 31st, 2023",Debre Berhan Comprehensive Specialized Hospital (governmental tertiary referral hospital),204,Adult patients (>18 years) admitted to the surgical ward for surgical procedures,"Adult patients of age > 18 years, patients on at least one prophylaxis antibiotic, and wounds classified as clean, clean-contaminated, and contaminated",Patients who received therapeutic antimicrobials during hospitalization before surgery for a comorbid condition; history of previous admission for a similar surgical procedure; incomplete information,34.13 ± 12.8 years (mean ± SD),26.50%,"General surgery, Orthopedics, Urology, Hernia repair, Head and neck surgery, and other (including appendectomy, graft, and breast surgery)","Gastrointestinal surgery, orthopedic surgery, urological surgery, hernia repair surgery, head and neck surgery, appendectomy, graft, breast surgery",Not Applicable,Not Applicable,Not Applicable,Not Applicable,22.1% of surgical antibiotic prophylaxis was appropriate as per guidelines,204,126,61.80%,Clinical signs and symptoms only (no laboratory confirmation),Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Inappropriate selection, timing, and duration of antimicrobial prophylaxis; absence of culture and sensitivity tests; use of broad-spectrum antibiotics (ceftriaxone) due to unavailability of first- and second-generation cephalosporins and low adherence to protocols",Recommendations for establishment of antimicrobial and diagnostic stewardship programs; inclusion of clinical pharmacists in surgical ward teams; procurement of appropriate prophylactic drugs like cefazolin,"Lack of laboratory diagnosis with culture and sensitivity; poor adherence to guidelines; inappropriate selection and duration of prophylactic antibiotics; absence of antimicrobial stewardship program; unavailability of recommended antibiotics (cefazolin); short study period and no data on some confounders (e.g., antiseptic use, sterilization methods, anesthesia type)",Data recommended to be used for future national surveillance studies and policy recommendations; need for antimicrobial and diagnostic stewardship programs; necessity to strengthen laboratory infrastructure for culture and sensitivity testing,Not Applicable,Not Applicable,The higher rate of SSI calls for the consideration of definitive laboratory diagnosis with culture and sensitivity study to enable recommended antibiotic usage. Policymakers should focus on implementing antimicrobial and diagnostic stewardship approaches and ensure proper surgical antibiotic prophylaxis usage according to guidelines. Clinical pharmacists should be included in ward teams and appropriate drugs procured.,No laboratory diagnosis of SSI or pathogen identification or resistance pattern; no economic or morbidity/mortality burden data; study limited to a single center and short duration; only clinical diagnosis for SSI.
"Hamudu Haitham, Helmut Nyawale, Vitus Silago, Mariam M. Mirambo, Phillipo L. Chalya, Stephen E. Mshana",2025,"Incidence, bacteriological profile and predictors of surgical site infections following limb amputation at Bugando medical centre and Sekou toure referral regional hospital, Mwanza, Tanzania",Tanzania,Longitudinal,March - July 2024,Bugando Medical Centre (tertiary referral hospital) and Sekou Toure Regional Referral Hospital (public regional facility),120,Patients undergoing limb amputations,All consenting patients who underwent limb amputation at Bugando Medical Centre and Sekou Toure Regional Referral Hospital between March and July 2024,Patients who previously undergone amputation in other healthcare facilities who were referred for stump revisions,Median 58 [IQR 43.5-66.5] years,46.70%,"General Surgery, Pediatric Surgery, Plastic Surgery, Orthopedic Surgery",Limb amputation (upper and lower limb; closed and open amputation),Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,120,36,30%,CDC criteria with clinical assessment and wound/pus swab for culture,30,Escherichia coli,"Ampicillin 86.7%, trimethoprim/sulphamethoxazole 80%, ceftriaxone 80%, ceftazidime 73.3%, gentamicin 73.33%, ciprofloxacin 60%, cefepime 60%, ceftriaxone/sulbactam 66.7%, amikacin 33.3%, piperacillin/tazobactam 53.3%; 0% resistance to meropenem",Staphylococcus aureus,"Ampicillin 57.14%, trimethoprim/sulphamethoxazole 57.14%, gentamicin 14.29%, ciprofloxacin 28.57%, amikacin 14.29%, vancomycin 0%, ceftriaxone not tested (NA)",Pseudomonas aeruginosa,"Ampicillin 75%, trimethoprim/sulphamethoxazole 75%, cefepime 0%, ceftazidime 25%, ceftriaxone 50%, ceftriaxone/sulbactam 75%, gentamycin 25%, amikacin 25%, piperacillin/tazobactam 50%; 0% resistance to meropenem",More than half of Gram-negative isolates were resistant to third and fourth generation cephalosporins; all Enterobacterales and non-fermenters sensitive to meropenem,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Transmission from health care environment; high use of third and fourth generation cephalosporins for prophylaxis,Recommendation to update antibiotic prophylaxis protocols tailored to local surveillance data; strengthen antimicrobial stewardship and infection prevention and control (IPC) programs,"Limited data on anaerobic bacteria due to lack of anaerobic cultures; superficial swab cultures may not always represent organisms causing deep wound infections; lack of reporting of resistance mechanism proportions in gram negatives (e.g. ampC, ESBL) and Gram-positives (MRSA); need for improved IPC and antibiotic stewardship",Mention of need to strengthen antimicrobial stewardship and infection prevention programs and tailor antibiotic protocols to local surveillance,Not Applicable,Not Applicable,"About one third of patients developed SSIs after limb amputation, with increased odds in younger age, smokers, higher ASA score, prolonged surgery, and blood transfusion. The predominance of multidrug resistant Gram-negative bacteria highlights urgent need to strengthen antimicrobial stewardship and IPC programs and to update management protocols based on local surveillance data.","No major ambiguities, but data on economic burden, length of stay, reoperation or readmission rates, and mortality attributable to SSI is missing/not reported."
"Kumburu Happiness Houka, Tolbert Sonda, Blandina Theophil Mmbaga, Michael Alifrangis, Ole Lund, Gibson Kibiki, Frank M. Aarestrup",2017,"Patterns of infections, aetiological agents and antimicrobial resistance at a tertiary care hospital in northern Tanzania",Tanzania,Descriptive analysis,August 2013 - August 2015,"Tertiary healthcare facility (Kilimanjaro Christian Medical Centre, Moshi, Tanzania)",575,"Patients admitted to medical and surgical departments; includes adults and children with various medical and surgical conditions, notably wound infections","Inpatients admitted to medical or surgical wards; patients diagnosed with wound infections, septicemia, diarrhoea, upper respiratory infection, or fever of unknown cause; informed consent obtained","Specimens with insufficient quantity, incomplete patient information",Median age 43 years (IQR 30-57),"39% female (n=227), 61% male (n=348)","General Surgery, Trauma, Burns, Diabetes-related wounds, Post-surgical wounds","Burn wound, motor traffic wound, post-surgical wound, diabetic wound, septic wound, animal bite wound, gunshot wound",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Clinical specimen collection from wounds/swabs; bacterial culture and identification using conventional and biochemical tests,293 (wound swab isolates),Proteus spp.,"Ampicillin 75%, Cefazolin 82.1%, Nalidixic acid 78.6%, Chloramphenicol 67.9%, Trimethoprim-sulfamethoxazole 64%, Ceftriaxone 53.6%, Ceftazidime 42.9%",Escherichia coli,"Ampicillin 68.4%, Cefazolin 57.9%, Nalidixic acid 52.6%, Trimethoprim-sulfamethoxazole 63.2%, Ceftriaxone 42.1%, Ceftazidime 36.8%, Amoxicillin-clavulanic acid 42.1%",Pseudomonas spp.,"Chloramphenicol 66.7%, Ceftazidime 18.2%, Gentamicin 13.6%, Ciprofloxacin 9.1%","Significant resistance observed to third-generation cephalosporins (ceftriaxone: Klebsiella spp. 53.8%, E. coli 42.1%; ceftazidime: Klebsiella spp. 46.2%, E. coli 36.8%) and gentamicin (Klebsiella spp. 38.5%, Proteus spp. 28.6%, E. coli 36.8%). MRSA (27.3% of S. aureus resistant to cefoxitin)",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Widespread use of antibiotics prior to admission (71.9% of patients); easy availability of antibiotics; self-medication; lack of policy to control improper use of antibiotics,"Recommendation for regular generation of local antimicrobial susceptibility data; establishment of sentinel surveillance sites; routine collection, analysis, and reporting of bacteriological and resistance data",Lack of active surveillance systems; absence of adequate and timely data on disease causes and control measures; need for strengthened diagnostic capacity at more sites; lack of structures for routine exchange and reporting of data; lack of national coordinating body for AMR surveillance,"Diagnostic capacity at a limited number of sites; recognition of need for sentinel surveillance and central organising body; currently, policies to control improper use of antibiotics are non-existent",Not Applicable,Not Applicable,"There is an alarming rate of antimicrobial resistance among a wide range of bacterial pathogens at the hospital, differing from high-income countries. Regular surveillance and reporting of aetiological agents and their resistance patterns are critical to guide treatment and policy. Establishment of sentinel sites and a central organising body for AMR data collection and reporting is urgently needed.","No data on direct SSI rates or attributable morbidity and mortality. The study analyses all wound infections, not solely surgical site infections. Sample size slightly inconsistent in sections (out of 575 enrolled, five excluded for incomplete info, and 590 specimens collected)."
"Ojulong Julius, T.P. Mwambu, M. Joloba, F. Bwanga, D.H. Kaddu-Mulindwa",2009,"Relative prevalence of methicilline resistant Staphylococcus aureus and its susceptibility pattern in Mulago Hospital, Kampala, Uganda",Uganda,Cross-sectional laboratory-based study,February to May 2007,"Mulago National Hospital (Tertiary referral, teaching and research hospital)",188,"Patients with surgical site infections from Surgical, Obstetrics, and Gynecology wards",Patients with surgical site infections yielding pus swabs for culture,Not Applicable,Not Applicable,Not Applicable,"General Surgery, Obstetrics & Gynecology",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,188 (patients with surgical site infections swabbed),Not Applicable,Clinical diagnosis with collection of pus swabs for microbiological identification,54 S. aureus isolates (from 188 SSI specimens); 17 MRSA isolates,Staphylococcus aureus,"MRSA resistance rates: 88.2% trimethoprim-sulfamethoxazole, 88.2% erythromycin, 58.8% gentamycin, 70.6% ciprofloxacin, 88.2% chloramphenicol, 100% penicillin, 0% vancomycin, 0% clindamycin (but 82.4% inducible resistance shown by D-test)",Not Applicable,Not Applicable,Not Applicable,Not Applicable,All MRSA isolates were susceptible to vancomycin (a WHO critically important antibiotic); 70.6% resistance to ciprofloxacin; 58.8% resistance to gentamycin,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"High cost and unavailability of alternative antibiotics (e.g., vancomycin) noted as an economic treatment consideration",Not Applicable,"Broad-spectrum antibiotic use, cross resistance among antibiotics, transmission via hand contamination, drug pressure in the community",Recommendation to perform routine D-test for inducible clindamycin resistance; highlight need for accurate laboratory detection and guided chemotherapy,Lack of routine D-test for inducible clindamycin resistance; absence of large-scale studies of MRSA susceptibility in the East African region; limited access to alternative antibiotics,Laboratory capacity to detect MRSA and perform susceptibility testing present at Makerere University; need for larger surveillance studies identified,Not Applicable,Not Applicable,High prevalence of multidrug-resistant MRSA among S. aureus isolates from surgical site infections. Vancomycin is currently the only consistently effective antimicrobial agent against MRSA in this setting. Routine D-test for inducible clindamycin resistance should be performed. Large studies across East Africa are needed to guide therapy.,"The study did not provide data on age or sex distribution, clinical morbidity outcomes, economic indirect costs, or other SSI pathogens. SSI rates per procedure and patient outcomes are not addressed. All data are based on microbiological analysis of surgical site infection swabs, not patient-level outcomes."
"Iyamba Jean-Marie Liesse, José Mulwahali Wambale, Cyprien Mbundu Lukukula, Ntondo za Balega Takaisi-Kikuni",2014,High prevalence of methicillin resistant staphylococci strains isolated from surgical site infections in Kinshasa,Democratic Republic of Congo,Laboratory-based cross-sectional study,January to October 2013,"Provincial General Reference Hospital of Kinshasa (HGPRK) and Clinic of University of Kinshasa (CUK), tertiary hospital structure",130,Hospitalized surgical patients with purulent lesions of infected surgical sites,Hospitalized surgical patients with infected sites and purulent lesions,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,130,Not Applicable,Wound swab collection from purulent infected sites; laboratory identification of staphylococcal strains using standard microbiological methods and latex agglutination test,"89 staphylococcal isolates (74 S. aureus, 15 CNS)",Staphylococcus aureus,"MRSA: 89.4% ampicillin, 76.6% cotrimoxazole, 76.6% erythromycin, 68% clindamycin, 57.4% ciprofloxacin, 57.4% cefotaxime, 53% ceftazidime; 19% vancomycin",Coagulase-negative staphylococci (CNS),"MR-CNS: 88.9% ampicillin, 100% cotrimoxazole, 77.8% erythromycin, 66.7% clindamycin, 100% ciprofloxacin, 66.7% cefotaxime, 44.6% ceftazidime",Not Applicable,Not Applicable,"All MRSA and MR-CNS strains were sensitive to imipenem (carbapenem) and most to vancomycin (19% MRSA resistant), multidrug resistance present",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,High-pressure use of broad-spectrum antibiotics and long hospital stays,Authors recommend antibiotic susceptibility testing prior to treatment; surveillance policy suggested as national priority,Lack of antibiotic surveillance policies and genomic characterization of S. aureus strains; limited data on MR-CNS prevalence,No national antibiotic surveillance policy in DRC,Not Applicable,Not Applicable,"High prevalence of multidrug resistant MRSA and MR-CNS strains isolated from SSIs; imipenem, amoxicillin-clavulanic acid, and vancomycin are the most active antibiotics; antibiotic surveillance policy should become national priority.","No data provided on age, sex, surgical specialty, specific procedures, or clinical outcomes. All SSI cases defined by positive wound culture; ambiguity in counting total SSIs versus total staphylococcal isolates."
"Manyahi Joel, Mecky I Matee, Mtebe Majigo, Sabrina Moyo, Stephen E Mshana, Eligius F Lyamuya",2014,"Predominance of multi-drug resistant bacterial pathogens causing surgical site infections in Muhimbili national hospital, Tanzania",Tanzania,Descriptive cross sectional,September 2011 - February 2012,"Muhimbili National Hospital (MNH), tertiary referral teaching hospital",100,"Patients aged 18-80 years with clinical evidence of surgical site infection from general surgery, obstetrics and gynecology, and orthopedic wards",Patients with clinical evidence of SSI as defined by CDC,Not Applicable,Range 18-80 years; Mean/SD not specified,47%,"General Surgery, Obstetrics & Gynecology, Orthopedics","Surgical debridement and external fixation (27%), laparotomy (25%), caesarean section (15%)",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,100,Not Applicable,Clinical evidence as defined by CDC criteria,147,Pseudomonas aeruginosa,"Resistant to ceftazidime (88%), gentamicin (8%), ciprofloxacin (8%), tetracycline (NA), meropenem (0%)",Staphylococcus aureus,"Penicillin (83%), ampicillin (92%), amoxycillin/clavulanic acid (73%), ceftriaxone (47%), gentamicin (33%), ciprofloxacin (29%), clindamycin (6%), erythromycin (39%), tetracycline (35%), co-trimoxazole (20%), chloramphenicol (47%)",Klebsiella pneumoniae,"Ampicillin (100%), amoxycillin/clavulanic acid (94%), ceftriaxone (81%), ceftazidime (88%), cefotaxime (88%), gentamicin (67%), ciprofloxacin (56%), tetracycline (56%), co-trimoxazole (94%), chloramphenicol (54%), meropenem (0%)","High resistance (67-100%) to 3rd generation cephalosporins (ceftriaxone, ceftazidime, cefotaxime) among Gram negative bacteria; All tested Gram negative isolates susceptible to meropenem; ESBL producers noted in E. coli (92.3%) and K. pneumoniae (69%)",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Prolonged hospital stay noted qualitatively, quantitative data not provided",Not Applicable,Not Applicable,"Inappropriate use of antimicrobial agents, high antimicrobial exposure (95% documented antimicrobial use within a month, 80% received ceftriaxone prophylaxis)",Recommendation for urgent revision of perioperative antimicrobial prophylaxis policy at national referral hospital,Cross-sectional design; lack of 30-day post-discharge follow up; need for standardized guidelines for antibiotic use and SSI management,Need for significant change in antibiotic prescription policy; current lack of standardized perioperative antimicrobial policy noted,Not Applicable,Not Applicable,"A high proportion of isolates (63%) causing SSIs were multidrug resistant, with 90% resistant to more than four classes of antibiotics; urgent revision of antibiotic policy is needed for rational and effective SSI management in the hospital.",No SSI incidence rate given; cross-sectional design and lack of post-discharge follow-up limit findings; sex breakdown unclear if 53% male/47% female or vice versa; sample size matches throughout; most data on resistance provided as percentages;
"Amulioto Johnstone, Margaret W. Muturi, Scholastica Mathenge, Gideon M. Mutua",2020,"Antibiotic susceptibility patterns of bacteria isolates from post-operative wound infections among patients attending Mama Lucy Kibaki Hospital, Kenya",Kenya,Cross-sectional descriptive study,October 2018 - March 2019,"Mama Lucy Kibaki Hospital, level 5 public health facility, Nairobi",58,"Patients of all age groups with surgical site infections following general, obstetrics, and gynecological surgeries","Patients of all age groups with surgical site infection following general, obstetrics and gynecological surgeries",Patients who did not consent,Mean age 31.12 years (range 7-61),67.20%,"General Surgery, Obstetrics & Gynecology",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,58,Not Applicable,Clinical evidence of infection (drainage from incision); identified by surgeons,78,Staphylococcus aureus,Methicillin-resistant S. aureus (MRSA) 65.4%; Ampicillin 95.5% resistant; Oxacillin 59.1% resistant; Azithromycin 45.5% resistant,Escherichia coli,Ampicillin 91.7% resistant; Amoxycillin 100% resistant; Multidrug resistance: resistance to ≥4 antibiotics,Acinetobacter species,Cefepime 100% resistant; Amikacin 100% resistant; Gentamicin 63.6% resistant; Chloramphenicol 18.2% resistant,High resistance of gram-negative rods to Cefepime and Amikacin; MRSA prevalence (resistance to Oxacillin),Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Irrational use of antimicrobial agents causing selective pressure; lack of effective surveillance programs,Not Applicable,Paucity of clinical microbiological data; lack of effective surveillance programs for SSI etiologies and their antibiograms,Not Applicable,Not Applicable,Not Applicable,There is high resistance to most drugs among gram-negative bacteria and a high proportion of MRSA. Continuous monitoring of susceptibility patterns is needed to assist with treatment and to monitor resistance trends.,"No information is provided on the specific surgical procedures performed or details on economic/hospital burden. SSI incidence rate refers to all consecutive identified SSI cases, so no denominator for rate calculation is given. No outcomes data (morbidity/mortality/hospital stay). Data on guideline adherence or national/regional policy response absent."
"Ojulong Julius, Tom Philip Mwambu, Moses Jolobo, Ezra Agwu, Freddie Bwanga, Christine Najjuka, D.H. Kaddu-Mulindwa",2010,"Prevalence of methicillin resistant staphylococcus aureus (MRSA) among isolates from surgical site infections in Mulago hospital-Kampala, Uganda",Uganda,Cross-sectional study,February 2007 - May 2007,"Mulago National Referral Hospital, Kampala, Uganda",188,Patients who underwent elective and emergency surgery at Mulago Hospital and developed surgical site infections during the study period,Patients who underwent elective and emergency surgery during the study period and developed surgical site infections after surgery as defined by Centers for Disease Control and Prevention criteria,Not Applicable,Mean age 31 years (range 13 - 87 years),37.10%,General Surgery,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,188 (all enrolled had SSI),Not Applicable,"Defined by Centers for Disease Control and Prevention (CDC) criteria (Horan et al, 1992)",54 (S. aureus isolates),Staphylococcus aureus,31.5% of S. aureus isolates were methicillin-resistant (MRSA) by PCR; MRSA is resistant to penicillins and all other ß-lactam antibiotics; nosocomial MRSA are also resistant to a variety of other antibiotic classes,Not Applicable,Not Applicable,Not Applicable,Not Applicable,MRSA isolates identified by mecA gene are resistant to all ß-lactam antibiotics including carbapenems,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Indiscriminate use of antibiotics, inappropriate use of antibiotics for community infections, lack of infection control measures, poor health education and low personal hygiene",Recommendation for preoperative MRSA screening and control of transmission to reduce SSI burden; no intervention tested in this study,Limited information on surgical site infections caused by MRSA in Uganda and other tropical African countries; need for research on sources of MRSA and factors linked to acquisition; distinction between community and hospital-acquired MRSA,Not Applicable,Not Applicable,Not Applicable,"S. aureus is highly (28.7%) prevalent in surgical site infections in Mulago National Referral Hospital, Kampala, Uganda. MRSA is highly (31.5%) prevalent among populations of S. aureus isolated from surgical site infections in Mulago National Referral Hospital, Kampala, Uganda.","All included patients had SSIs, so the sample size equals total SSIs. No data on outcomes such as mortality, reoperation, hospital stay, costs. Study focuses only on S. aureus and MRSA prevalence and resistance."
"Jung L, Kiwanuka J, Mbabazi L, Nakate V, Musaazi J, Nabaja H, Kajumbula H, Lubbert C, Mwaka E, Nsibirwa S, von Braun A",2023,A case for routine microbial diagnostics: Results from antimicrobial susceptibility testing in post-traumatic wound infections at a Ugandan tertiary care hospital,Uganda,Prospective cross-sectional observational study,October 2021 - January 2022,"Department of Orthopedics/Trauma, Mulago National Referral Hospital (tertiary government hospital)",124,"Patients of all age groups with clinical signs of wound infection following trauma, primarily admitted for musculoskeletal injuries due to road traffic accidents",Patients of all age groups on the orthopedic/trauma unit who developed clinical signs of wound infection (e.g. erythema /pus discharge) and/or fever,"Patients without clinical signs of wound infection but fever due to malaria or acute, untreated tuberculosis and patients participating in another study",Median 30 years (IQR 23-39),20.2% female (n = 25/124),Orthopedics and Trauma Surgery,"Debridement, external fixation, amputation, fasciotomy, wire osteosynthesis, screw/plate osteosynthesis, intramedullary nailing, Achilles tendon repair, incision and drainage, plaster of Paris back slab, skeletal traction",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,112 patients underwent surgery; multiple procedures per patient (details in table); specific total number of procedures not stated,Not Applicable,Not Applicable,"Diagnosis based on clinical signs of wound infection (erythema, pus discharge, fever); wound swabs and blood cultures for microbial confirmation",238 isolates from 122 positive wound swabs,Escherichia coli,95.7% resistant to ceftriaxone/cefotaxime; 55% to gentamicin; 63.6% to ciprofloxacin; 43.5% to piperacillin/tazobactam; 2.2% to carbapenems; 100% to ampicillin; 43.7% to amoxicillin-clavulanic acid,Acinetobacter spp.,80% to cefepime; 81.3% to ciprofloxacin; 82.1% to gentamicin; 74.4% to piperacillin/tazobactam; 35.7% to carbapenems,Klebsiella spp.,93.8% resistant to ceftriaxone/cefotaxime; 77.8% to gentamicin; 38.5% to ciprofloxacin; 50% to piperacillin/tazobactam; 12.5% to carbapenems; 27.8% to amoxicillin-clavulanic acid,Acinetobacter spp. showed 35.7% resistance to carbapenems; E. coli 2.2% resistance to carbapenems; Klebsiella spp. 12.5% resistance to carbapenems,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Median 22 days (IQR 15-41),Not Applicable,Not Applicable,"Overuse of ceftriaxone (peri-operative prophylaxis and prolonged post-op use), low compliance with national guidelines, lack of local empirical guidelines, self-medication and OTC antimicrobial purchases, incomplete documentation, limited diagnostic capacity and surveillance gaps",Implementation and provision of routine microbial diagnostics and antimicrobial susceptibility testing for all recruited patients; costs covered by study,"Lack of access to routine microbial diagnostics, insufficient diagnostic capacity, lack of locally adapted empirical prescribing guidelines, low compliance with clinical guidelines, lack of data from routine care, high prevalence of self-prescription","Uganda has a National Action Plan on AMR (2018); WHO GLASS aligned surveillance started in 2015; but no national lab-based surveillance system for routine care established; expertise in labs focused on other diseases (HIV, malaria, TB, COVID-19), diagnostics mostly paid out-of-pocket",Not Applicable,Not Applicable,Current empiric antibiotic treatment for wound infections misses its target due to very high resistance rates; routine pathogen identification and AST are urgently needed to improve care and address rising AMR; expanding diagnostic capacity and antimicrobial stewardship programs is essential.,"SSI incidence and direct cost data not reported; study focuses on wound infections following trauma, which may not fully overlap with defined SSIs; several limitations acknowledged regarding generalizability and sample collection; no risk of bias tool reported."
"Boru Kalicha, Alqeer Aliyo, Derese Daka, Tibeso Gamachu, Oliyad Husen, Zekarias Solomon",2025,"Bacterial surgical site infections: prevalence, antimicrobial susceptibility patterns, and associated risk factors among patients at Bule Hora University Teaching Hospital, Southern Ethiopia",Ethiopia,Cross-sectional study,1 January – 30 June 2023,Bule Hora University Teaching Hospital (tertiary-level public hospital),183,Patients who underwent surgical treatment during the study period and exhibited signs of surgical site infection,"All patients with signs of SSI, based on criteria stated by WHO and CDC during the data collection period","Patients with incomplete charts, those who underwent surgery at another institution, and those with nonoperative wounds or abscesses",31.65 (SD 19.357) years; range 1–95 years,44.8% female (n=82),Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,29,"15.8% (95% CI, 10.9–22)","Clinical assessment by physician; features including pain, redness, swelling, discharge, fever; followed CDC (and WHO) criteria; culture confirmation",41,Staphylococcus aureus,"Penicillin (78.6%), ceftazidime (78.6%), cefoxitin (57.1%, indicating MRSA), amoxicillin (35.7%)",Coagulase-negative staphylococci,"Penicillin (71.4%), ceftazidime (57.1%)",Escherichia coli,"Ampicillin (83.3%), ceftazidime (83.3%), amoxicillin (66.7%), penicillin (66.7%)",8/14 S. aureus isolates (57.1%) resistant to cefoxitin (MRSA); high resistance to 3rd generation cephalosporins in E. coli and other Gram-negatives,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Loss of daily wages mentioned as an impact but no quantitative data provided,"Frequent and inappropriate use of antimicrobial agents, self-medication practices, antibiotics are easily obtainable and used without a prescription","Recommendation to establish a functional microbiology laboratory, review infection prevention practices, and limit the use of certain antibiotics","Need for routine screening and antimicrobial susceptibility testing, need for studies including fungi and anaerobic bacteria, call for nationwide survey of SSIs and antimicrobial resistance","Patients with SSI received care according to national standards; recommendation for improved laboratory infrastructure, routine surveillance, and infection prevention",Not Applicable,Not Applicable,"High prevalence of SSIs and multidrug-resistant isolates compared to WHO or previous studies. Routine screening and susceptibility testing are needed. Significant risk factors include older age, longer hospital stay, extended operative times, and malnutrition.",No specific breakdown by surgical specialty or procedure; no economic cost quantification; no hospital stay or morbidity/mortality outcomes reported.
"Velin Lotta, Theoneste Nkurunziza, Grace Umutesi, Gilbert Rukundo, Robert Riviello, Jean De Dieu Gatete, Moses Muwanguzi, Ivan Emil, Lisa M. Bebell, Bethany L. Hedt-Gauthier, Marthe Yankurije, Fredrick Kateera, Kara Faktor",2021,Surgical Site Infections and Antimicrobial Resistance After Cesarean Section Delivery in Rural Rwanda,Rwanda,Prospective cohort study,"September 23, 2019 - March 16, 2020",Kirehe District Hospital (Governmental hospital supported by Partners In Health-Rwanda),795,Women who underwent cesarean deliveries at a rural Rwandan district hospital,"Women who delivered via cesarean section at Kirehe District Hospital between September 23, 2019, and March 16, 2020 and for whom study-related follow-up was feasible, before COVID-19 distancing policies were implemented",Women from Mahama Refugee Camp were excluded due to inability to complete study activities; Women unable to be followed up before COVID-19 restrictions,Not Applicable,100%,Obstetrics & Gynecology,Cesarean section delivery,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,795,45,5.70%,Clinical diagnosis by trained GPs using CDC guidelines; confirmed by wound examination at POD 11 (+/- 3 days),57,Coagulase-negative staphylococci (CoNS),"Penicillin (100% resistant), cefoxitin (71% resistant), TMP-SMX (82% resistant), clindamycin (55% resistant), tetracycline (55% resistant), levofloxacin (29% resistant)",Acinetobacter baumannii complex,"Ceftriaxone (100% resistant), cefepime (78% resistant), gentamicin (56% resistant), tetracycline (56% resistant), TMP-SMX (67% resistant), imipenem (11% intermediate/resistant)",Proteus species,"Ampicillin (100% resistant), ceftriaxone (88% resistant), cefepime (88% resistant), gentamicin (13% resistant), amikacin (63% resistant), ciprofloxacin (63% resistant), levofloxacin (67% resistant), piperacillin-tazobactam (25% resistant), TMP-SMX (63% resistant), imipenem (38% resistant)","All gram-negative pathogens showed high levels of resistance or intermediate susceptibility to ceftriaxone (92.1%) and cefepime (84.6%). All isolates tested were resistant to cefazolin and aztreonam. All Acinetobacter, Klebsiella, Proteus, and Enterobacter cloacae isolates demonstrated non-susceptibility to imipenem.",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Misuse and overuse of antibiotics, frequent use of ampicillin pre- and post-operatively, empiric prescription based on availability and provider preference, inconsistent adherence to WHO guidelines",Training of general practitioners in CDC SSI diagnosis; use of Levine technique for swab collection; attempted adjustment of treatment based on microbiology results,Need for research on risk factors contributing to high prevalence of gram-negative and resistant pathogens; lack of effective treatment options due to increasing resistance; lack of evidence-based protocols for rational use of antibiotics at district hospitals; limitations of wound cultures and microbiology in resource-limited settings; limited adherence to guidelines on antibiotic prophylaxis,"Samples processed by Rwanda National Reference Laboratory, but resource constraints identified; challenges in procurement of standard laboratory media",Not Applicable,Not Applicable,"Bacterial isolates from SSI swab cultures in rural Rwanda predominantly consisted of gram-negative pathogens and were largely resistant to commonly used antibiotics. This raises concerns about the effectiveness of antibiotics currently used for surgical prophylaxis and treatment, and may guide appropriate selection of treatment of SSIs in rural Rwanda and comparable settings. Additional research is needed to determine risk factors contributing to the high prevalence of gram-negative and resistant pathogens.",Mean/median age and measures of additional morbidity/mortality are not reported. No formal risk of bias tool is mentioned. Adherence to guidelines is only discussed narratively; no percentage given. The sample size for antibiotic resistance results sometimes varies due to the addition of antibiotics to testing panel after the study began.
"Burugu Magdaline, Andrew Nyerere, Susan Odera, Lameck Ontweka",2022,"Occurrence of Post-Surgical Wound Infections, Bacterial Isolates, and their Susceptibility to Commonly Used Antibiotics at Kenyatta National Hospital, Kenya",Kenya,Cross-sectional,Not Applicable,Tertiary referral and teaching hospital (Kenyatta National Hospital),62,Adult male and female patients admitted at the surgical ward after undergoing surgery,"Adults (>18 years), undergone surgery at KNH, identifiable superficial SSI (purulent exudate, swelling, erythema, pain, local temperature, peri wound cellulitis or surgeon's diagnosis after the surgical period), consented to participate","Immunocompromised patients, those on long term corticosteroid treatment",Not Applicable,40.3,General Surgery,"Incision & drainage, herniorraphy, appendectomy, open reduction internal fixation (ORIF), laparotomy, breast surgery, corrective surgery",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,62,Not Applicable,"Clinical signs (purulent exudate, swelling, erythema, pain, local temperature, peri wound cellulitis) or surgeon's diagnosis",54,Staphylococcus aureus,Methicillin (Oxacillin) - 56.3%; Augmentin - 62.5%; Erythromycin - 56.3%; Ampicillin - 56.3%; Cotrimoxazole - 50%; Vancomycin - 31.3%,Escherichia coli,Ceftriaxone - 91.7%; Ampicillin - 83.3%; Ciprofloxacin - 33.3%; Augmentin - 50%; Ceftazidime - 41.7%; Amikacin - 41.7%; Cefotaxime - 66.7%; Cefuroxime - 25.0%,Pseudomonas aeruginosa,Amikacin - 71.4%; Cefepime - 85.7%; Piperacillin - 42.9%; Timentin - 57.1%; Meropenem - 14.3%,E. coli high resistance to ceftriaxone (91.7%); P. aeruginosa resistance to meropenem (14.3%); Gram-negatives highly resistant to ceftriaxone,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Overuse and misuse of antibiotics; irrational antibiotic prescriptions; over the counter sale of antibiotics without prescription; poor quality drugs and dumping of banned products into the market,Emphasis on infection control and prevention measures; recommendation for continuous surveillance and genotypic characterization of clinical isolates,Need for continuous surveillance and genotypic characterization; future studies needed on anaerobic bacteria; lack of National surveillance systems of antibiotic resistant organisms,Need to develop national surveillance of antibiotic resistant organisms; current lack of such systems mentioned,Not Applicable,Not Applicable,"Control and prevention measures should be put into place as a strategy to minimize the incidence of SSIs and the spread of resistant isolates; careful selection of antibiotic regimen for treating SSIs is necessary to minimize increasing magnitude of drug resistance; SSIs should be tracked, analyzed, and monitored; prevention is key due to difficulty of treatment for highly resistant isolates.","No data found on SSI incidence rate (since all participants had an SSI); no information on age distribution, study period, direct/indirect costs, hospital length of stay, or morbidity/mortality rates."
"Mukagendaneza Marie Josée , Emmanuel Munyaneza, Esperance Muhawenayo, Dancilla Nyirasebura, Egide Abahuje, John Nyirigira, Jean De Dieu Harelimana, Thierry Zawadi Muvunyi, Florence Masaisa, Jean Claude Byiringiro, Theobald Hategekimana, Claude Mambo Muvunyi",2019,"Incidence, root causes, and outcomes of surgical site infections in a tertiary care hospital in Rwanda: a prospective observational cohort study",Rwanda,Prospective observational cohort study,"October 10, 2017 - February 12, 2018",Tertiary referral hospital (University Teaching Hospital of Kigali),294,"Adult patients (≥18 years) undergoing elective or emergency surgical procedures in the general surgery, orthopedics, or urology departments",Patients 18 years old and above undergoing surgery as elective or emergency procedures and developing wound infection within the stipulated duration of the study,Patients having another operation within one month preceding the study period,Mean 40.41 years (SD 16.7),31%,"Orthopedics, General Surgery, Urology",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,294,34,10.90%,Clinical assessment and wound swab/culture; SSI classified by CDC criteria (all superficial),32,Klebsiella ssp,"Resistance rates: amoxy-clavilinic acid (98.8%), gentamicin (92.6%), ciprofloxacin (78.1%), ceftriaxone (53.3%); 100% sensitive to amikacin and imipenem",Escherichia coli,"Not separately listed; from all isolates: amoxy-clavilinic acid (98.8%), gentamicin (92.6%), ciprofloxacin (78.1%), ceftriaxone (53.3%), 100% sensitive to amikacin and imipenem",Proteus ssp,"Not separately listed; see overall profile: high resistance rates, 100% sensitive to amikacin and imipenem",53.3% resistance to ceftriaxone; 100% sensitivity to imipenem (carbapenem) and amikacin,Not Applicable,Not Applicable,Not Applicable,0% (No deaths in SSI patients reported),Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Easily availability and inappropriate use of antibiotics, poor personnel hygiene, faecal contamination, post procedural contamination and outbreaks, lack of strict infection control",Recommendations for periodic surveillance of bacteria and antibiotic susceptibility; implementation of strict protocol for antibiotic administration and operating room regulations,"Lack of published reports on SSI risk factors, microbial pathogens and their antibiotic profile; need for regular surveillance and strict protocol implementation",Not Applicable,Not Applicable,Not Applicable,"SSI incidence rate was within acceptable international ranges but multi drug resistance was seen in half of the isolates, limiting treatment options. Significant associations with wound class, longer surgery, longer hospital stay, surgeon experience, and emergency surgeries. Recommendation for periodic surveillance and improved protocols.","No distinction in resistance rates between pathogen species; mortality data limited; details of direct or indirect costs, length of hospital stay, re-operation, and readmission rates not provided."
"Mengesha RE, Kasa BG, Saravanan M, Berhe DF, Wasihun AG",2014,"Aerobic bacteria in post surgical wound infections and pattern of their antimicrobial susceptibility in Ayder Teaching and Referral Hospital, Mekelle, Ethiopia",Ethiopia,Prospective cross-sectional study,January to June 2012,Ayder Teaching and Referral Hospital (tertiary referral hospital),128,"Patients post-surgery in general surgery and orthopedic wards, with clinical signs of post surgical wound infection",Patients who had undergone surgery in the hospital and developed SSI as diagnosed clinically by physicians within 30 days of post surgical procedure,"Surgical patients with community-acquired pyogenic infections (abscess, furuncle, carbuncles); patients with infection of episiotomy; patients with open fractures",Mean 35.95 ± 19.01 years,30/128 (23.4%),"General Surgery, Orthopedics",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,610 (during study period); 128 developed clinical SSI and included,128 (inclusion: all had clinical SSI),"Not specified as % among all operated, but 128/610 (21%) developed clinically-diagnosed SSI; and 75% (96/128) of suspected SSIs were culture-positive","Clinical diagnosis by physicians (symptoms of infection), with confirmation by wound swab aerobic culture",123,Staphylococcus aureus,"90% resistance to Tetracycline, Ceftriazone, Ampicillin; 85% resistance to Cloxacilline; 100% sensitive to Vancomycin",Klebsiella spp.,100% resistant to Amoxicillin; 93.1% resistance to Tetracycline; 89.7% resistance to Ampicillin; 86.2% resistance to Ceftriazone; 27.8% resistance to Gentamicin,Coagulase negative Staphylococci (CoNS),88.9% resistance to Amoxicillin; 77.8% resistance to Amoxicillin-clavunilic acid; 77.8% resistance to Ampicillin; 77.8% resistance to Tetracycline; 100% sensitive to Vancomycin,"High resistance to third generation cephalosporin (Ceftriazone) seen in Klebsiella spp. (86.2%), P. aeruginosa (100%), S. aureus (90%)",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Indiscriminate use and easy availability of antibiotics without proper prescription; irrational prescriptions,Periodic surveillance of bacteria and antibiotic susceptibility recommended by authors to prevent further emergence and spread of resistant pathogens,Scarcity of local/regional surveillance data on SSI pathogens and resistance; inability to isolate anaerobic bacteria and fungi; lack of standardization of SSI diagnostic criteria,Not Applicable,Not Applicable,Not Applicable,Surgical site wound infection rate was high (75%) and multidrug-resistance was seen in 82.92% of isolates. Periodic surveillance of bacteria and antibiotic susceptibility is needed to prevent emergence and spread of resistant pathogens.,"The sample size in the results (128) matches methods. SSI incidence is only among clinically suspected cases (not all operations), so 21% SSI by clinical diagnosis in all surgical patients during the study period but not rigorously reported as SSI incidence rate among all surgeries. No outcome/morbidity/mortality data provided."
"Abayneh Mengistu, Molla Asnake, Dassalegn Muleta, Asnake Simieneh",2022,"Assessment of Bacterial Profiles and Antimicrobial Susceptibility Pattern of Isolates Among Patients Diagnosed with Surgical Site Infections at Mizan-Tepi University Teaching Hospital, Southwest Ethiopia: A Prospective Observational Cohort Study",Ethiopia,Prospective Observational Cohort Study,June to September 2021,"Mizan-Tepi University Teaching Hospital, tertiary referral hospital",262,Patients of all ages undergoing surgical procedures at Mizan-Tepi University Teaching Hospital,All patients who underwent a surgical procedure at Mizan-Tepi university teaching hospital during the study period and were followed for 30 days post-operation.,"Patients who developed postoperative wound infections later than 30 days, patients with infected burn wounds, and those with an initial diagnosis suggestive of infection.",Not Applicable,59.60%,"General Surgery, Obstetrics & Gynecology, Genitourinary, Head and neck, Hernia repair, Vascular, Skin grafting, Hepatobiliary","Cesarean section, gastrointestinal surgeries, genitourinary surgeries, head and neck surgeries, hernia repair, vascular surgeries, skin grafting, lipoma excision, hepatobiliary surgeries",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,262,33,12.60%,CDC-NHSN and WHO criteria for SSI; clinical assessment by surgeons and attending physicians; laboratory culture for confirmation,41,Escherichia coli,"Ampicillin 100%, Amoxicillin-clavulanic acid 91.7%, Ceftriaxone 75%, Cefoxitin 83.3%, Gentamicin 58.3%, Ciprofloxacin 50%, Doxycycline 66.7%, Cotrimoxazole 75%, Chloramphenicol 75%, Meropenem 16.7%, Amikacin 0%",Staphylococcus aureus,"Ampicillin 87.5%, Amoxicillin-clavulanic acid 75%, Doxycycline 75%, Cotrimoxazole 75%, Clindamycin 75%, Erythromycin 75%, Gentamicin 62.5%, Chloramphenicol 62.5%, Cefoxitin (MRSA marker) 37.5%, Amikacin 0%",Proteus species,"Ampicillin 100%, Amoxicillin-clavulanic acid 83.3%, Ceftriaxone 66.7%, Cefoxitin 66.7%, Gentamicin 50%, Ciprofloxacin 50%, Doxycycline 66.7%, Cotrimoxazole 83.3%, Chloramphenicol 66.7%, Amikacin 0%, Meropenem 0%","Resistance to 3rd generation cephalosporins (e.g. ceftriaxone rates: 50-83.3% for Gram-negatives); meropenem resistance rare (7.3% in Gram-negatives), no resistance to amikacin",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Frequent and inappropriate use of antibiotics for therapeutic and prophylactic purposes; increased use of broad-spectrum antibiotics such as ceftriaxone.,Periodic surveillance of bacterial profile and antibiotic susceptibility testing; implementation of strict protocol for antibiotic administration and operative room regulation.,Small number of patients with SSIs limits ability to estimate true prevalence of AMR; lack of use of blood agar medium; lack of molecular techniques to further characterize resistance; results may not be generalizable to other settings.,"Ethical approval and local permission were obtained; laboratory performed cultures and susceptibility testing with standard methods, but limited by resources.",Not Applicable,Not Applicable,"Prevalence of SSIs remains high; majority of isolates were Gram-negative and multidrug-resistant; clinicians have few treatment options, emphasizing need for surveillance and strict protocols for antibiotic use and operative room practices.","No data on mean/median age, additional hospital stay, re-operation, mortality, or economic costs presented. Bacterial resistance patterns reported as percentages per organism; amikacin and meropenem retained high activity. Study population covers all surgical patients, but breakdown of age/stats only by groups. Small SSI case count and lack of blood agar use noted as limitations by authors."
"Scherbaum Micha, Katrin Kösters, Raymund Egid Mürbeth, Ulysse Ateba Ngoa, Peter Gottfried Kremsner, Bertrand Lell, Abraham Alabi",2014,"Incidence, pathogens and resistance patterns of nosocomial infections at a rural hospital in Gabon",Gabon,Prospective surveillance study,January to July 2009,"Albert Schweitzer Hospital, rural tertiary regional hospital",2925,"Patients admitted to the departments of surgery, gynecology/obstetrics and internal medicine","All patients admitted to study departments and screened daily for signs and symptoms of nosocomial infections; further evaluation for patients with new occurrence of fever (>38°C) at least 48 hours after admission, repeated fever after a non-febrile interval of 72 hours, signs of surgical site infection, or reopening of the operation site due to infection",Not Applicable,Median 30 (IQR 22-42) years for all patients; Median 41 (IQR 33-69) years for patients with nosocomial infections,65%,"General Surgery, Obstetrics & Gynecology","abdominal hysterectomy, caesarean section, appendectomy, myomectomy, salpingectomy (ectopic pregnancy), herniotomy",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,1059,20,1.9% (95% CI 1.1 - 2.7%) per operation,Clinical assessment with microbiological confirmation where possible; classification based on Robert Koch Institute definitions as per CDC guidelines,"Not directly stated; most frequent pathogen in SSI: S. aureus (9 isolates in SSI); total Gram-positive and Gram-negative bacteria: 36 and 34, respectively",Staphylococcus aureus,0/14 sensitive to penicillin; 14/14 sensitive to cloxacillin,Escherichia coli,1/14 (7%) sensitive to ampicillin; 6/14 sensitive to amoxicillin-clavulanic acid; 9/14 (64%) sensitive to ceftriaxone; 9/14 (64%) sensitive to gentamicin; 9/14 (64%) sensitive to ciprofloxacin; 3/12 sensitive to cotrimoxazole; 5/14 (36%) ESBL producers,Enterococcus spp.,0/9 sensitive to penicillin; 9/9 sensitive to ampicillin,"E. coli: Only 64% sensitive to ceftriaxone (a 3rd gen cephalosporin); K. pneumoniae: Only 50% sensitive to ceftriaxone, ciprofloxacin and gentamicin; ESBL production noted in E. coli (36%) and K. pneumoniae (50%)","Patients with nosocomial infections stayed a mean of 27 days (range 4-108), which is 23 days longer than the average patient",Not Applicable,Not Applicable,Not Available specifically for SSI; but 11% of patients with nosocomial infections died,Not Applicable,Not Applicable,Mean stay for nosocomial infection patients: 27 days (range: 4-108); Median 22 (IQR 13-34) days,Not Applicable,Not Applicable,High use of antibiotics in the hospital and as outpatients; antibiotics freely available over the counter; inappropriate use of anti-infectious medications including routine long duration prophylaxis,"Recommendations for infection control interventions, improved perioperative prophylaxis, antibiotic stewardship measures, quality management, and personnel capacity building",Lack of microbiological laboratory infrastructure in small rural hospitals; lack of regional surveillance data; inability to detect post-discharge infections; limited treatment options for ESBL pathogens; need for sound surveillance and competent microbiology,"Microbiological lab available at facility, but no effective antibiotics for ESBL strains; surveillance recommended as mandatory; need for capacity building highlighted",Not Applicable,Not Applicable,"High rates of surgical site infections and multi-resistant pathogens necessitate urgent comprehensive infection control interventions. The overall incidence of nosocomial infections was low, but higher rates were seen after gynecological operations. Surveillance and improved use of antibiotics are needed. Many Gram-negative bacteria display resistance to commonly prescribed antibiotics, and antibiotics for ESBL strains are not available.",No direct SSI mortality is reported; some granularity is lost in data on pathogen isolates for SSI specifically; ESBL rates are pooled for E. coli and Klebsiella across infection types.
"NIHR Global Health Research Unit on Global Surgery, Dr Shereen Rachel Varghese, Dr Elizabeth Li",2024,"Microbiology testing capacity and antimicrobial drug resistance in surgical-site infections: a post-hoc, prospective, secondary analysis of the FALCON randomised trial in seven low-income and middle-income countries","Benin, Ghana, Nigeria, Rwanda, South Africa (ECSA countries only; also India and Mexico were included in the overarching trial)",Post-hoc prospective secondary analysis of a Randomised Controlled Trial,"December 10, 2018 - September 7, 2020",54 hospitals (multiple tertiary and district hospitals) in seven countries,5788 (FALCON trial); 1163 with SSI included in this analysis,Patients undergoing abdominal surgery with an incision of 5 cm or greater,"All eligible, consecutive patients undergoing abdominal surgery with incision ≥5 cm; stratified by intraoperative contamination level; patients with SSI diagnosed by CDC criteria included in this analysis",Patients undergoing clean operations (gastrointestinal tract not entered); patients without SSI for this sub-analysis,Mean 35.6 years (SD 18.3) for SSI patients,57.6% female among SSI patients,"General Surgery (abdominal surgery); also includes subgroups such as obstetric, trauma, malignant, and benign abdominal surgery",Abdominal surgery with incision ≥5 cm; further breakdown not provided,266 alcoholic chlorhexidine + triclosan-coated suture; 286 alcoholic chlorhexidine + non-coated suture; 300 povidone-iodine + triclosan-coated suture; 284 povidone-iodine + non-coated suture (within SSI cohort),Randomised to 2% alcoholic chlorhexidine or 10% aqueous povidone-iodine skin preparation and either triclosan-coated or non-coated sutures,N/A (all groups received active interventions; analysis is on SSI subgroup across all trial arms),Not Applicable,Not directly reported; regular infection control teams in 21-44% of hospitals; overall guideline adherence not quantified,5788 (full trial); 1163 with SSI,1163,"22.0% (1163 of 5284, 95% CI 20.9–23.2) among eligible trial patients",CDC criteria for surgical-site infection,235 (from 228 patients swabbed),Escherichia coli,"64% AMR reported in meta-analysis; 69.4% MDR among all isolates with MDR data; specific rates for E. coli not extracted in primary article but overall high resistance to 3rd-gen cephalosporins (48.1%), 2nd-gen cephalosporins (77.4%), fluoroquinolones (42.2%), antipseudomonal penicillins (43.1%)",Klebsiella spp.,"Up to 85% AMR to 3rd-gen cephalosporins (meta-analysis), 51.1% MDR overall in isolates",Staphylococcus aureus,48% methicillin resistance (meta-analysis); specific in-study resistance rates not disaggregated,"High resistance to 3rd-generation cephalosporins (48.1%), carbapenems tested but not quantified; gentamicin susceptibility 17.8%, fluoroquinolones susceptibility 11.2%, chloramphenicol best at 24.2%",Not Applicable,11.5% (131/1138 with SSI),12.0% (136/1138 with SSI),2.5% (29/1163 with SSI) died (attributable specifically to SSI not detailed),2.5% in SSI cohort,Not Applicable,Not Applicable,Not Applicable,Catastrophic health expenditure for patients and families discussed but not quantified,"Inappropriate antimicrobial use, poor infection prevention and control practices, limited access to microbiology diagnostics, overuse and misuse of antimicrobials, widespread lack of local guidelines","Implementation of infection control teams, development of local guidelines, use of targeted perioperative antibiotic prophylaxis, expansion of testing capacity; reference to ChEETAh trial (glove/instrument change before wound closure)","Limited microbiology testing capacity, lack of local guidelines on antimicrobial prophylaxis, insufficient infection control teams, inadequate surveillance and laboratory infrastructure","Reference to Fleming Fund (UK) supporting AMR surveillance capacity; Africa CDC identifying AMR as urgent public health threat; hospitals surveyed for capacity, routine screening for ESBL, MRSA, VRE, and CPE was variable",STROBE checklist (used for reporting); study protocol referenced,"Not directly reported; limitations include inability to classify MDR in all microorganisms, post-hoc analysis, missing reasons for lack of wound swabs","Systemic weaknesses exist in the testing capacity and prevention of MDR in LMIC hospitals. These weaknesses are associated with non-targeted antibiotic use and high levels of AMR. Expansion of testing capacity, local guideline development, and implementation of infection control teams could reduce the burden of MDR in SSIs.","Sample size and subgroup numbers are complex; numbers in some trial arms may differ due to exclusions and missing data. Data on direct/indirect costs and detailed procedure types were not reported. Pathogen-specific resistance rates are mostly from referenced meta-analysis, not this study's primary data."
"De Nardo P., E. Gentilotti, B. Nguhuni, F. Vairo, Z. Chaula, E. Nicastri, M.M. Nassoro, N. Bevilacqua, A. Ismail, A. Savoldi, A. Zumla, G. Ippolito",2016,Post-caesarean section surgical site infections at a Tanzanian tertiary hospital: a prospective observational study,Tanzania,Prospective observational cohort study,"August 19, 2013 - approximately November 19, 2013","Dodoma Regional Referral Hospital (DRRH), Gynaecology and Obstetrics Department, tertiary referral hospital",467,Pregnant women who underwent elective or emergency caesarean section,All pregnant women admitted to the DRRH Labour Ward who underwent an elective or emergency caesarean section and were enrolled within 24 h post CS,Not attending any clinical visit after CS and failed telephone contact (197 out of initial 664 lost to follow-up),Not Applicable,100%,Obstetrics & Gynecology,Caesarean section (midline vertical and Pfannestiel incisions),Not Applicable,Not Applicable,Not Applicable,Not Applicable,2.1% received pre-incision antibiotic prophylaxis; only two (0.4%) received it at the correct time (30-60 min before incision),467,225,48.20%,"Clinical examination at follow-up visits, CDC criteria, structured telephone interview and algorithm",106,Coagulase-negative Staphylococcus spp.,Not Applicable,Staphylococcus aureus,MRSA accounted for 79% (34/43) of S. aureus isolates,"Gram-negative bacteria (E. coli, Proteus spp., Coliform, Klebsiella spp., Pseudomonas aeruginosa)",Not Applicable,"High MRSA prevalence (79%) among S. aureus isolates, possibly related to inappropriate use of third-generation cephalosporins",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Average length of stay post-CS for all women was 2 days; majority discharged within 3 days after CS,Not Applicable,Not Applicable,"Inappropriate use of antibiotics (esp. third-generation cephalosporins), lack of antimicrobial stewardship, possible healthcare-associated infections, overcrowding of labour and post-delivery wards",On-the-job training and supervision for junior doctors in theatre recommended; ongoing coordinated interventions of infection prevention and antimicrobial stewardship at DRRH,"High rate of SSI, lack of consistent protocol for antibiotic prophylaxis, need for review of national guidelines and internal protocols, incomplete screening for diabetes, high rate of lost to follow-up",No consistent protocol for antibiotic prophylaxis available; majority of women tested for HIV as per national guidelines; ongoing intervention to revise surgery and antibiotic protocols at DRRH,Not Applicable,Not Applicable,"The incidence of post-caesarean section SSI at DRRH was extremely high (48.2%), with most infections detected within nine days post-surgery and a very high prevalence of MRSA. Urgent interventions are needed for infection prevention and control, antimicrobial stewardship, and improvement of evidence-based surgical and antibiotic protocols.","Study had a high rate of loss to follow-up (29.7%); age statistics not reported; resistance data only for MRSA; no morbidity, mortality, or economic impact data presented."
"Abosse Samuel, Chalachew Genet, Awoke Derbie",2021,"Antimicrobial Resistance Profile of Bacterial Isolates Identified from Surgical Site Infections at a Referral Hospital, Northwest Ethiopia",Ethiopia,Hospital based cross-sectional study,"1 February to 30 June, 2019","Felege Hiwot Referral Hospital, Bahir Dar (tertiary referral hospital)",165,"Patients with clinically diagnosed surgical wound infection admitted to surgical, orthopedic, and medical wards","Patients clinically diagnosed for surgical wound infection available in surgical ward, outpatient department and medical ward during the study period and gave written informed consent/assent","Patients clinically diagnosed as having surgical wound infection in surgical, orthopedic, and medical wards but unconscious during the study period",Not Applicable,40.6,"General Surgery, Orthopedics, Medicine (based on surgical, orthopedic and medical wards)",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,115,69.70%,Clinical assessment and culture confirmation (conventional bacteriological technique),125,Staphylococcus aureus,"Amoxicillin: 87.1%, Ampicillin: 71.0%, Oxacillin: 32.3%, Erythromycin: 38.7%, Gentamycin: 16.1%, Ciprofloxacin: 16.1%, Chloramphenicol: 35.5%, Tetracycline: 38.7%, Vancomycin: 9.7%, Clindamycin: 25.8%",Pseudomonas aeruginosa,"Ampicillin: 84.6%, Meropenem: 23.1%, Gentamycin: 38.5%, Ciprofloxacin: 19.2%, Chloramphenicol: 34.6%, Tetracycline: 50.0%, Augmentin: 53.9%, Cefotaxime: 61.5%, Cefoxitin: 57.7%, Ceftazidime: 53.9%",Klebsiella species,"Ampicillin: 82.4%, Meropenem: 11.8%, Gentamycin: 11.8%, Ciprofloxacin: 23.5%, Chloramphenicol: 29.4%, Tetracycline: 58.8%, Augmentin: 47.1%, Cefotaxime: 52.9%, Cefoxitin: 58.8%, Ceftazidime: 52.9%","Meropenem (carbapenem) resistance: P. aeruginosa 23.1%, Klebsiella spp. 11.8%, E. coli 16.7%; Cefotaxime (3rd gen cephalosporin) resistance rates for Gram-negatives between 52.9%-81.8%",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Overuse and misuse of antimicrobials, weak regulatory practice, inadequate bacteriological surveillance, lack of routine antimicrobial susceptibility testing facilities, availability of antimicrobials for purchase without prescription",Recommendation for regular surveillance on types of bacterial isolates and drug resistance patterns; rational use of antimicrobials,No attempt to isolate anaerobic pathogens; species-level identification of some genera not done due to resource limitation,Mention of inadequate bacteriological surveillance and lack of routine antimicrobial susceptibility testing facilities,Not Applicable,Not Applicable,"S. aureus, P. aeruginosa, and Klebsiella species are the most common isolates from surgical wounds and show high rates of multidrug resistance; regular surveillance and rational antibiotic use should be strengthened in the study area.","No direct data on surgical procedure type, costs, re-operation/readmission, or mortality is provided. Age data stratified by categories only; no mean/median. Some specialties (medical ward) could include non-surgical patients if wound is present. No risk of bias assessment reported."
"Worku Seble , Tamrat Abebe, Ashenafi Alemu, Berhanu Seyoum, Göte Swedberg, Alemseged Abdissa, Adane Mihret, Getachew Tesfaye Beyene",2023,Bacterial profile of surgical site infection and antimicrobial resistance patterns in Ethiopia: a multicentre prospective cross-sectional study,Ethiopia,Multicentre prospective cross-sectional study,July 2020 - August 2021,"University Teaching Hospitals: Debre Tabor Comprehensive Specialized Hospital, Hawassa University Teaching Hospital, Jimma University Teaching Specialized Hospital, Tikur Anbessa Specialized Hospital",752,Patients of all ages with clinically suspected surgical site infection admitted for elective and emergency surgery,"All patients with suspected SSI admitted for elective and emergency surgery, who developed signs and symptoms of SSI within 30 days post-op (or 90 days for implants), who provided consent/assent","Patients on antibiotics within preceding ten days, SSI later than 30 days after operation, refusal to consent/assent, infected burn wounds",Median age 28 years (range 3 days to 85 years),44.40%,"General surgery, orthopedic surgery, pediatric surgery, obstetrics and gynecology wards",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,752 (study population were SSIs),Not Applicable,"Clinical diagnosis by attending physicians; laboratory confirmation by wound discharge culture and identification (MALDI-TOF, Gram stain, biochemical tests)",494,Staphylococcus aureus,"Penicillin 90.1%, Ampicillin 76.5%, Clindamycin 7.8%, Chloramphenicol 10.6%, Gentamicin 12.4%, Cefoxitin (methicillin resistance) 22.7%, Vancomycin 0%",Escherichia coli,"Ampicillin 94.6%, Ceftriaxone 99%, Cefotaxime 93.8%, Ceftazidime 79.4%, Cefepime 77%, Cefuroxime 73.5%, Ampicillin-sulbactam 72%, TMP-SMX 71.5%, Tetracycline 70.6%, Gentamicin 57.8%, Chloramphenicol 41.2%, Ertapenem 24.5%, Imipenem 11.6%, Amikacin 10.8%, Meropenem 9.8%",Klebsiella pneumoniae,"Ampicillin 100%, Ceftriaxone 100%, Cefotaxime 93.8%, Amoxicillin-clavulanic acid 91.7%, Ceftazidime 88.5%, Cefepime 81.2%, Cefuroxime 77.1%, Tetracycline 66.7%, Ertapenem 43.8%, Meropenem 41.7%, Amikacin 33.3%, Imipenem 29.2%","Carbapenem resistance in Enterobacteriaceae: meropenem 17.6%, imipenem 20.3%, ertapenem 32.9%. E. coli: ertapenem 24.5%, imipenem 11.6%, meropenem 9.8%. Klebsiella pneumoniae: ertapenem 43.8%, meropenem 41.7%, imipenem 29.2%. A. baumannii: ertapenem 92.1%, meropenem 84.2%, imipenem 65.9%. All S. aureus sensitive to vancomycin.",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Broad-spectrum or inappropriate antibiotics use, lack of antimicrobial stewardship, misuse/overuse of antibiotics, un-updated empirical therapy",Standard bacteriological tests and routine antimicrobial susceptibility testing (AST); recommendation for antimicrobial stewardship and empirical therapy guided by local AST,"Scarcity of ongoing surveillance data, reliance on phenotypic lab methods in prior studies, lack of AMR data in previous work; limited ability to investigate anaerobic bacteria or fungi due to lab resource constraints",Hospitals have started establishing bacteriology labs and AST capacity with external support; need for regular national surveillance and monitoring of AMR patterns,Not Applicable,Not Applicable,"E. coli and S. aureus are the leading SSI isolates in Ethiopia. High antimicrobial resistance exists, especially to ceftriaxone and carbapenems. Emergence of diverse and new bacterial etiologies was noted. Effective antimicrobial stewardship and routine AST are critical. National-level surveillance and guideline adherence are needed to curb rising MDR SSI.","Specific procedures performed not detailed in the text. Outcomes regarding morbidity, mortality, hospital burden, and costs not reported. Sample size matches across sections. All AMR data referenced laboratory-based resistance rates."
"Worku Seble, Tamrat Abebe, Berhanu Seyoum, Ashenafi Alemu, Yidenek Shimelash, Marechign Yimer, Alemseged Abdissa, Getachew Tesfaye Beyene, Göte Swedberg, Adane Mihret",2023,Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus among Patients Diagnosed with Surgical Site Infection at Four Hospitals in Ethiopia,Ethiopia,Multicenter Cross-sectional study,July 2020 - August 2021,"Four university teaching hospitals (Debre Tabor Comprehensive Specialized Hospital, Tikur Anbessa Specialized Hospital, Hawassa University Teaching Hospital, Jimma University Teaching Hospital)",752,"Patients of all ages admitted for elective and emergency surgery in general surgery, gynecology/obstetric, and orthopedics wards who developed SSI within 30 days post-operation","All surgical patients, regardless of age, who underwent surgery during the study period and developed signs and symptoms of SSI within 30 days","Patients who developed SSIs after 30 days following the operation, those who refused to participate, patients with infected burn wounds, and those on treatment",Mean 35 ± 28.3 years; Median 30 years,41.7,"General Surgery, Gynecology/Obstetrics, Orthopedics",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,752,Not Applicable,"Clinical diagnosis, confirmed by wound culture",163 S. aureus isolates; 40 MRSA isolates (cefoxitin resistant); 11 mecA gene-positive Staphylococci,Staphylococcus aureus,"24.5% of S. aureus isolates were MRSA (resistant to penicillins, cephalosporins, and carbapenems, except ceftaroline/ceftobiprole); among MRSA, 12.9% carried mecA gene; 0.6% showed vancomycin resistance",Mammaliicoccus sciuri (formerly Staphylococcus sciuri),Six isolates (15% of cefoxitin-resistant isolates); 83.3% carried mecA gene; all were vancomycin sensitive,Staphylococcus warneri / Staphylococcus haemolyticus / Staphylococcus epidermidis (each n=1),"S. haemolyticus: mecA positive and vancomycin resistant; S. warneri: mecA positive, vancomycin sensitive; S. epidermidis: cefoxitin resistant, mecA and femA negative","MRSA resistant to penicillins, cephalosporins, carbapenems. One S. haemolyticus isolate showed vancomycin resistance (MIC > 8 ug/mL)",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Age ≥ 61 years, prolonged hospital stay (≥7 days), previous antibiotic use, and antimicrobial prophylaxis during operation associated with higher risk of MRSA SSI","Prompt infection prevention and control measures, strict adherence to infection prevention methods, periodic surveillance, and initiation of antimicrobial stewardship programs recommended",Molecular epidemiology of MRSA and VRSA poorly documented in Ethiopia; need for tailored strategies to control MRSA in specific hospitals; further investigation of non-aureus Staphylococci as reservoirs for mecA gene and potential for gene transfer,Hospitals have microbiology laboratories for culture and susceptibility testing; authors highlight need for periodic surveillance and antimicrobial stewardship at hospital level,Not Applicable,Not Applicable,"High prevalence of mecA carriage among CoNS and variable epidemiology of MRSA between hospitals. Older age, longer hospital stays, previous antibiotic use, and certain prophylaxis practices are risk factors. Infection control and stewardship programs are essential.","No direct reporting of SSI incidence rate or total procedures performed. Clinical outcomes such as morbidity, mortality, and hospital burden not reported. Antibiotic resistance patterns for pathogens other than S. aureus are limited to gene carriage. Pathogen 3 field merged due to single isolates. Study focused on molecular epidemiology and risk factors, not direct clinical or economic outcomes."
"Worku Seble, Tamrat Abebe, Berhanu Seyoum, Bikila Alemu, Gebrie Denkayehu, Tamrayehu Seyoum, Dawit Hailu Alemayehu, Alemseged Abdissa, Getachew Tesfaye Beyene, Adane Mihret, Göte Swedberg",2024,Molecular characterization of carbapenemase and extended spectrum beta-lactamase producing Acinetobacter baumannii isolates causing surgical site infections in Ethiopia,Ethiopia,Multicenter cross-sectional study,July 2020 - August 2021,"Four tertiary referral hospitals (Debre Tabor Comprehensive Specialized Hospital, Hawassa University Comprehensive Specialized Hospital, Jimma University Specialized Hospital, Tikur Anbessa Specialized Hospital)",752 SSI patients enrolled (493 culture positive),Patients of all age groups diagnosed with surgical site infection admitted to four Ethiopian referral hospitals,"All age groups; patients diagnosed with SSI confirmed clinically at the hospital; diagnosis confirmed as SSI (pain, redness, edema, tenderness, gaping, abscess or purulent discharge, fever >38°C) within 30 days of operation for those without implant",Patients who had been on antibiotics within the preceding ten days,Median 30 years (range 5 days - 70 years),48.8% female (21/43 Acinetobacter-positive patients),"General Surgery, Orthopedics, Paediatrics/ICU",Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,752 wound cultures performed (one per SSI patient),752 (clinically diagnosed),Not Applicable,"Clinical assessment by surgeon: infection characterized by pain, redness, edema, tenderness, gaping, abscess/purulent discharge, fever >38°C within 30 days of operation for those without implant",493 culture-positive isolates (43 Acinetobacter species),Acinetobacter baumannii,"93% ESBL positive (by CDT); 95.3% resistant to ceftriaxone; 46.5% harbored carbapenemase genes; carbapenem and cephalosporin resistance genes (blaOxA-23, blaOxA-69, blaNDM-1, blaCTX-M-15); high prevalence of multidrug resistance",Acinetobacter pittii,"Both isolates (2) 100% positive for beta-lactamase genes, 100% ESBL and ceftriaxone resistance",Acinetobacter soli,Both isolates (2) negative for beta-lactamase genes; 100% ceftriaxone resistance,85.7% of Acinetobacter isolates carbapenem resistant; detection of blaNDM-1 genes conferring resistance to carbapenems; 95.3% resistant to cephalosporins (ceftriaxone),Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Extensive antibiotic misuse, poor stewardship, co-existence of multiple resistance genes, horizontal gene transfer via plasmids, use of third-generation cephalosporins, and carbapenems",Strict infection prevention and control procedures in health facilities; recommendation for effective antibiotics stewardship,"Small number of Acinetobacter isolates, possibly not representative for the community; scarcity of data on genetic epidemiology of resistant Acinetobacter in East African countries; need for improved detection and surveillance","Reference quality control procedures; lab capacity for MALDI-TOF MS, PCR, and whole-genome sequencing performed at national institutes; recommendation for national antimicrobial policy and infection control",Not Applicable,Not Applicable,"The frequency and co-existence of ESBL and carbapenemase-producing genes in Acinetobacter species, particularly A. baumannii, is extremely alarming and calls for strict infection prevention and control procedures and effective antibiotic stewardship. The emergence of multidrug-resistant Acinetobacter may significantly limit treatment options in Ethiopian hospitals.","Sample size for Acinetobacter isolates is small; no information on specific surgical procedures, economic outcomes, morbidity/mortality rates, or comparator/intervention groups. Most data focused on molecular resistance epidemiology; SSI incidence rate per procedure is not explicitly stated."
"Wekesa Yvonne N, Fatuma Namusoke, Musa Sekikubo, Dennis Wandera Mango, Freddie Bwanga",2020,"Ceftriaxone- and ceftazidime-resistant Klebsiella species, Escherichia coli, and methicillin-resistant Staphylococcus aureus dominate caesarean surgical site infections at Mulago Hospital, Kampala, Uganda",Uganda,Cross-sectional study,November 2017 - April 2018,"Mulago National Referral Hospital, Kampala (tertiary public referral and teaching hospital)",109,Women who had undergone caesarean section and developed surgical site infection within 30 days,"Women with clinical features of post-caesarean section surgical site infection within 30 days, defined by CDC criteria (purulent discharge, pain/tenderness, swelling, redness/heat, purulent discharge from drain, diagnosis of SSI by doctor, abscess at clinical/radiologic exam, or wound dehiscence, with/without systemic symptoms)",Women with clinical features of post-C/S SSI who declined to participate or were too ill to consent,"Median 25 years (IQR 10), range 16–41 years",100%,Obstetrics & Gynecology,Caesarean section,Not Applicable,Not Applicable,Not Applicable,Not Applicable,"Not directly reported; practice described as routine use of ceftriaxone and/or metronidazole perioperatively, not in line with recommended guidelines",Not Applicable,109,Not Applicable (All subjects had SSI),"Based on CDC criteria; clinical signs within 30 days of C/S, culture confirmation",118,Klebsiella species,97.7% resistant to ceftriaxone; 90.9% to ceftazidime; 100% to ampicillin; 95.5% amoxicillin/clavulanic acid; 47.7% ciprofloxacin; 34.1% carbapenems; 43.2% ESBL-producers,Staphylococcus aureus,91.2% MRSA; 97.1% penicillin; 97.1% trimethoprim/sulfamethoxazole; 70.6% erythromycin; 58.8% D-test positive (inducible clindamycin resistance); 52.9% gentamicin; 50% ciprofloxacin; 44.1% tetracycline; 20.6% chloramphenicol. All susceptible to vancomycin,Escherichia coli,"100% resistant to ceftriaxone, ceftazidime, ampicillin, amoxicillin/clavulanic acid, trimethoprim/sulfamethoxazole; 81.8% ciprofloxacin; 63.6% gentamicin; 27.3% chloramphenicol; 0% carbapenems; 90.9% ESBL-producers",34.1% of Klebsiella species and 0% E. coli resistant to carbapenems (WHO critical antibiotics),Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Not Applicable,Routine use and possible overuse of broad-spectrum antibiotics (ceftriaxone) for prophylaxis and treatment of C/S and SSIs; lack of routine culture and susceptibility testing,Recommendation for routine culture and AST (antimicrobial susceptibility testing) for SSIs to guide therapy; suggestion to review guidelines on prophylaxis and first-line treatment,"Lack of routine surveillance, culture and susceptibility testing; inappropriate and routine use of broad-spectrum antibiotics for prophylaxis and treatment; limited choice of effective oral antibiotics; sample size limitations; inability to test all drugs due to procurement issues",No mention of specific national/regional policy responses; notes limited routine surveillance and lack of culture/AST infrastructure,Not Applicable,Not Applicable,"Klebsiella species, E. coli and S. aureus (majority MRSA) dominated C/S SSIs at Mulago Hospital, with almost all Klebsiella and E. coli resistant to third-generation cephalosporins; ESBLs drive resistance in E. coli but carbapenemase is increasing among Klebsiella; high MRSA prevalence among S. aureus; current empirical treatments (ceftriaxone/metronidazole) likely ineffective, urgent need for routine culture and AST to guide therapy and review of prophylaxis/treatment guidelines.","No data on outcome measures such as mortality, morbidity, total hospital stay, economic impact; all patients were female; some drugs (piperacillin-tazobactam, cefoxitin) not tested due to procurement issues; sample size noted as a limitation by authors."
